Methods for improving production of biological products by reducing level of endogenous protein

By reducing endogenous protein levels in production cells through genetic modifications, the yield and quality of recombinant polypeptides are significantly improved, addressing the high production costs of mammalian cell line technologies.

JP2024161560AInactive Publication Date: 2024-11-19LONZA AG
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
JP2024139532
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2018-07-13
Filing Date
2024-08-21
Publication Date
2024-11-19
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The high costs associated with producing recombinant therapeutic proteins in mammalian cell lines result in increased global healthcare expenses, necessitating the development of methods to enhance yield and reduce production costs.

Method used

Reducing the level of endogenous proteins in production cells through genetic modifications such as deletions, substitutions, or insertions in regulatory nucleic acid sequences, or using siRNA to bind to promoters or enhancers, thereby increasing the availability of cellular resources for recombinant polypeptide production.

Benefits of technology

This approach enhances the specific production rate, growth rate, and product yield of recombinant polypeptides, improving productivity and product quality by reducing endogenous protein interference in the production process.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024161560000001_ABST
    Figure 2024161560000001_ABST
Patent Text Reader

Abstract

To satisfy the need to develop and produce methods for the yield of products, e.g., polypeptides, expressed in cultured cells.SOLUTION: The present disclosure features methods, cells or cell lines, and compositions for increasing the amount of products, e.g., proteins, produced by cells or cell lines by reducing the level of non-essential endogenous proteins.SELECTED DRAWING: Figure 1A
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to U.S. Provisional Application No. 62 / 697,480, filed July 13, 2018, the contents of which are incorporated herein by reference in their entirety.

[0002] The present disclosure relates to methods and compositions for modifying expressing host cells to increase the yield of a product, eg, a polypeptide, expressed in cultured cells. [Background technology]

[0003] Cellular products, such as recombinant therapeutic proteins, are commonly expressed in cellular expression systems, such as mammalian cell expression systems. Hundreds of market-approved biopharmaceuticals are expressed in mammalian cell lines. However, the high costs associated with their production result in increased global healthcare costs.

[0004] Thus, a need exists to develop and produce methods for the yield of products, such as polypeptides expressed in cultured cells. Summary of the Invention

[0005] The present disclosure is based, in part, on the discovery that reducing the level of one or more endogenous proteins, e.g., non-essential proteins, redundant proteins, and / or secreted endogenous proteins, in a cell, e.g., a production cell, capable of producing a product, e.g., a recombinant polypeptide, increases the yield of the product.

[0006] In one aspect, the invention provides a method for producing a product, such as a recombinant polypeptide, in a cell, such as a production cell, comprising: Reducing the level of an endogenous protein in a cell, such as a production cell; and producing a product therefrom.

[0007] In another aspect, the invention provides a method for producing a product, such as a recombinant polypeptide, in a cell, such as a production cell, comprising: Providing a cell, such as a production cell; Reducing the level of an endogenous protein in a cell, such as a production cell; Culturing the cells under suitable conditions to produce a product, such as a recombinant polypeptide; and producing a product therefrom.

[0008] In another aspect, the invention relates to a cell, e.g., a production cell, capable of producing a product, e.g., a recombinant polypeptide, where the cell, e.g., the production cell, comprises a deletion, substitution, or insertion mutation in a copy of a gene encoding an endogenous protein, or a regulatory nucleic acid sequence, such as a promoter or enhancer, operably linked to a gene encoding an endogenous protein, e.g., the mutation reduces expression levels of the endogenous protein.

[0009] In another aspect, the invention relates to a cell, e.g., a production cell, capable of producing a product, e.g., a recombinant polypeptide, wherein the cell comprises, e.g., a nucleic acid, such as an mRNA, encoding an endogenous protein, or a siRNA capable of binding to a regulatory element, such as a promoter or enhancer, operably linked to a gene encoding an endogenous protein.

[0010] In another aspect, the invention relates to a product, such as a recombinant polypeptide, produced by the methods or cells described herein.

[0011] In another aspect, the invention relates to pharmaceutical compositions comprising the products described herein, eg, recombinant polypeptides.

[0012] In another embodiment, the invention relates to an siRNA capable of binding to a nucleic acid, such as an mRNA, encoding an endogenous protein selected from Table E5.

[0013] In embodiments, the product, eg, a polypeptide, is one of the polypeptides provided in Tables 1 and 2, or a variant thereof.

[0014] In an embodiment, the product is a polypeptide. In an embodiment, the polypeptide is an antibody such as a monoclonal antibody, for example, an IgG1 antibody, or a polynucleotide encoding an antibody. In an embodiment, one or more cysteines in the antibody-encoded polynucleotide are replaced with another amino acid. In an embodiment, one or more cysteines are replaced with one or more serine residues.

[0015] In one aspect, the disclosure features a method for producing a product described herein in a cell, e.g., a recombinant host cell, e.g., a production cell. In some embodiments, the product is a polypeptide, e.g., a recombinant polypeptide.

[0016] Examples of products that may be produced using any of the methods or compositions described herein include recombinant products, or products in which at least one portion or part is the result of genetic engineering. The recombinant products described herein are useful for diagnostic or therapeutic purposes. In one embodiment, the product comprises a polypeptide, e.g., an antibody molecule (e.g., bispecific or multi-format antibody molecule), a fusion protein, or a protein conjugate. The methods and compositions described herein may be particularly useful for products that are difficult to produce, e.g., in high quantities or in sufficient quality for commercial or therapeutic use, such as next-generation biologics (e.g., fusion proteins, bispecific or multi-format antibody molecules, multimeric proteins, and glycosylated proteins). In one embodiment, the cells described herein, e.g., for producing a product, express the product. In one embodiment, the cells comprise an exogenous nucleic acid encoding a product described herein, such as a polypeptide selected from Tables 1, 2, 3, or 4. Additional examples of products are described in the section entitled "Products."

[0017] The methods described herein can also result in improved product quality compared to cells that are not subjected to low temperature. Improved product quality can be characterized by one or more of the following: dissociation (e.g., reduced dissociation of polypeptides into less active forms), aggregation (e.g., reduced clumps or aggregation), proper folding or assembly (e.g., reduced misfolded or unfolded products, or partially assembled or degraded products), post-translational modification (e.g., increased or reduced glycosylation heterogeneity, higher percentage of desired or predetermined post-translational modifications), fragmentation (e.g., reduced fragmentation), disulfide bond scrambling (e.g., reduced undesired isoforms or structures resulting from disulfide bond scrambling). In one embodiment, the quality of a product, such as a recombinant polypeptide, is increased by 1-fold, 2-fold, 5-fold, 10-fold, 20-fold, 50-fold, 100-fold, for example, compared to the quality of a product produced by cells that are not subjected to reduced temperature.

[0018] In embodiments, the methods for producing the products described herein can be carried out with one or more additional steps to enhance the stability or activity of the polypeptide. These include, but are not limited to, introducing modifications to the producing cells that improve ER processivity (ER augmentation) or secretion, obtaining the product from the cells or progeny of the cells or from the medium conditioned by the cells, isolating the product from at least one cell or medium component, and / or analyzing the product, for example, for activity or for the presence of a structural moiety. In one embodiment, the method further comprises a step of improving ER processivity (or ER expansion) by introducing a nucleic acid encoding PD1, BiP, ERO, or XBP1. In one embodiment, the method further comprises an additional step of improving secretion capacity or secretion rate by modulating the snare mechanism or other mechanisms involved in the secretory pathway, for example, by introducing a nucleic acid encoding a snare component.

[0019] product Suitable products for the methods described herein include polypeptides such as recombinant proteins, nucleic acid molecules such as DNA or RNA molecules, multimeric proteins or complexes, lipid-encapsulated particles such as virus-like particles, vesicles, or exosomes, or other molecules.In some embodiments, the product is a polypeptide such as a recombinant polypeptide.For example, the recombinant polypeptide can be a protein that is difficult to express, or a protein with a complex and / or non-native structure, such as a next-generation biological protein, such as a bispecific antibody molecule, a fusion protein, or a glycosylated protein.

[0020] In any of the methods described herein, the method of producing the product further comprises introducing an exogenous nucleic acid encoding the product, such as a polypeptide, e.g., a recombinant polypeptide, into the cell.

[0021] In any of the compositions, preparations, bioreactors, or methods described herein, the product, such as a recombinant polypeptide, is a therapeutic polypeptide, or an antibody molecule, such as an antibody or an antibody fragment thereof. In one embodiment, the antibody molecule is a monoclonal antibody. In one embodiment, the antibody molecule is a bispecific antibody molecule, such as BiTE (bispecific T cell engager), DART (biaffinity retargeting or redirecting T cells).

[0022] In one embodiment, the product, such as a recombinant polypeptide, is selected from Table 1, Table 2, Table 3, or Table 4.

[0023] In an embodiment, the product is stably expressed by the cell. In an embodiment, the exogenous nucleic acid encoding the product, such as a recombinant polypeptide, is integrated into the chromosomal genome of the cell. Alternatively, the product is transiently expressed by the cell. In an embodiment, the exogenous nucleic acid encoding the product, such as a recombinant polypeptide, is not integrated into the chromosomal genome of the cell.

[0024] host cell Provided herein are cells, such as recombinant cells, for producing the products described herein, e.g., production cells, methods of engineering such cells, and methods for using the cells.

[0025] In any of the compositions, preparations, or methods described herein, the cell is a eukaryotic cell. In one embodiment, the cell is a mammalian cell, a yeast cell, an insect cell, an algae cell, or a plant cell. In one embodiment, the cell is a rodent cell. In one embodiment, the cell is a CHO cell. Examples of CHO cells include, but are not limited to, CHOK1, CHOK1SV, Potelligent CHOK1SV, CHO GS knockout, CHOK1SV GS-KO, CHOS, CHO DG44, CHO DXB11, CHOZN, or CHO-derived cells.

[0026] In any of the compositions, preparations, or methods described herein, the cells are selected from the group consisting of HeLa, HEK293, H9, HepG2, MCF7, Jurkat, NIH3T3, PC12, PER.C6, BHK, VERO, SP2 / 0, NS0, YB2 / 0, EB66, C127, L cells, COS, e.g., COS1 and COS7, QC1-3, CHOK1, CHOK1SV, Potelligent CHOK1SV, CHO GS knockout, CHOK1SV GS-KO, CHOS, CHO DG44, CHO DXB11, and CHOZN.

[0027] In one embodiment, the cell is a eukaryotic cell other than a mammalian cell, such as an insect, plant, yeast, or algae cell. In one embodiment, the cell is a prokaryotic cell.

[0028] In any of the methods or cells, e.g., production cells, described herein, the cells express or contain a product, e.g., a recombinant product, e.g., a next generation biologic selected from the group consisting of a bispecific antibody, a fusion protein, or a glycosylated protein.

[0029] In any of the methods or cells, e.g., production cells, described herein, the cell is a CHO cell selected from the group consisting of CHOK1, CHOK1SV, Potelligent CHOK1SV, CHO GS knockout, CHOK1SV GS-KO, CHOS, CHO DG44, CHO DXB11, CHOZN, or a CHO derived cell.

[0030] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used to practice or test the present invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In addition, the materials, methods, and examples are illustrative only and are not intended to be limiting. Headings, subheadings, or numbered or lettered elements, such as (a), (b), (i), etc., are presented merely for ease of reading. The use of headings or numbered or lettered elements herein does not require the steps or elements to be performed in alphabetical order, nor does the steps or elements necessarily have to be discrete from one another. Other features, objects, and advantages of the present invention will become apparent from the description and drawings, and from the claims. [Brief description of the drawings]

[0031] [Figure 1A] Figure 1 shows a graph of cell-specific productivity of Mabs in CHO cell lines in which selected non-essential, redundant, and / or secreted endogenous proteins were knocked out compared to CHO cells transfected with vectors lacking gRNA. [Figure 1B] 1 shows a graph of genetic indel success as measured by TIDE analysis of genomic DNA extracted from FACS sorted pools. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0032] The present disclosure features methods and compositions for obtaining higher yields of products, e.g., polypeptides, by reducing the levels of endogenous proteins, e.g., non-essential proteins, redundant proteins, and / or secreted endogenous proteins, in cells, e.g., producing cells, capable of producing the product. The methods and cells used in the methods described herein exhibit improved quality compared to the yields and quality obtained from current production methods and / or cells. The methods and compositions described herein can also be used with engineered cells or cell lines that have improved productivity, product quality, robustness, and / or culture viability compared to cell expression systems currently used to produce recombinant products.

[0033] This method is suitable for the production of next-generation biological products. As these methods continue to gain therapeutic utility in patients, there will be an increasing demand for large quantities of next-generation biological products with high quality for therapeutic use, as well as efficient means for production and efficient development of production cell lines. Furthermore, many next-generation biological products are difficult to express and produce in conventional cell lines using conventional expression techniques known in the art. Current methods are not sufficient to produce these products in large quantities and with the high quality required for clinical use. The methods described herein include reducing the level of endogenous proteins and can be combined with other methods to overcome these obstacles and increase product yield.

[0034] definition Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art related to the present invention.Any method and material similar or equivalent to those described herein can be used to carry out and / or test the present invention, but preferred materials and methods are described herein.In the description and claims of the present invention, the following terms are used according to the definitions provided.

[0035] It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting.

[0036] The articles "a" and "an" are used herein to refer to one or more (i.e., at least one) of the grammatical subject of the article. By way of example, a "cell" can mean one cell or two or more cells.

[0037] As used herein, "endogenous" refers to any material that is naturally produced from or within an organism, cell, tissue, or system.

[0038] As used herein, "exogenous" refers to any material that is introduced into or produced outside of an organism, cell, tissue, or system. Thus, "exogenous nucleic acid" refers to a nucleic acid that is introduced into or produced outside of an organism, cell, tissue, or system. In one embodiment, the sequence of the exogenous nucleic acid is not naturally produced or cannot be found in the organism, cell, tissue, or system into which the exogenous nucleic acid is introduced. In an embodiment, a non-naturally occurring product, or a product that contains a non-naturally occurring portion, is an exogenous material with respect to the host cell described herein.

[0039] "Heterologous" as used herein refers to any material from one species when introduced into an organism, cell, tissue or system from a different species. In embodiments, heterologous material also encompasses material that contains parts from more than one species, or parts that do not occur naturally. As an example, in one embodiment, a nucleic acid encoding a fusion protein in which part of the fusion protein is human, part of the fusion protein is bacterial, and part of the fusion protein is non-natural, and the nucleic acid is introduced into a human cell, is a heterologous nucleic acid.

[0040] "Peptide", "polypeptide" and "protein", as used interchangeably herein, refer to a compound composed of amino acid residues covalently linked by peptide bonds or by means other than peptide bonds. A protein or peptide must contain at least two amino acids, with no limit placed on the maximum number of amino acids that a protein or peptide sequence may contain. In an embodiment, a protein may contain more than one, e.g., two, three, four, five, or more polypeptides, each associated with another polypeptide by either covalent or non-covalent bonds / interactions. A polypeptide includes any peptide or protein that contains two or more amino acids linked together by peptide bonds or by means other than peptide bonds. As used herein, the term refers to both short chains, e.g., also commonly referred to in the art as peptides, oligopeptides, and oligomers, as well as longer chains, commonly referred to in the art as proteins, of which there are many varieties. "Polypeptides" include, for example, biologically active fragments, substantially homologous polypeptides, oligopeptides, homodimers, heterodimers, mutants of polypeptides, modified polypeptides, derivatives, analogs, fusion proteins, and the like.

[0041] "Recombinant product" refers to a product that can be produced by a cell or a cell-free system. The product may be a molecule, a nucleic acid, a polypeptide (e.g., SS polypeptide), or any hybrid thereof. A recombinant product is one in which at least one component of the product, or at least one nucleotide of a sequence that controls the production or expression of the product, has been formed by genetic engineering. The genetic engineering used herein to generate recombinant products or constructs encoding recombinant products includes recombinant DNA expression techniques known in the art (e.g., as described in Current Protocols in Molecular Biology), site-directed, scanning, or random mutagenesis, CRISPR strategies, and zinc finger nuclease (ZFN) strategies. In one embodiment, the recombinant product is a recombinant polypeptide. In one embodiment, the recombinant product is a naturally occurring product. In one embodiment, the recombinant product is a non-naturally occurring product, e.g., a synthetic product. In one embodiment, one portion of the recombinant product is naturally occurring, while another portion of the recombinant product is non-naturally occurring. In another embodiment, a first portion of the recombinant product is one naturally occurring molecule, while another portion of the recombinant product is another naturally occurring molecule that is different from the first portion.

[0042] "Recombinant polypeptide" refers to a polypeptide that can be produced by a cell as described herein. A recombinant polypeptide is one that has been genetically engineered or manipulated (of a cell or progenitor cell) to form at least one nucleotide of a sequence that encodes the polypeptide or at least one nucleotide of a sequence that controls the expression of the polypeptide. For example, at least one nucleotide has been modified, e.g., it is the product of a rearrangement that has been introduced into or genetically engineered into a cell. In one embodiment, the sequence of the recombinant polypeptide is the same as that of a naturally occurring or non-naturally occurring isoform of the polypeptide or protein. In one embodiment, the amino acid sequence of the recombinant polypeptide is different from that of a naturally occurring or non-naturally occurring isoform of the polypeptide or protein. In one embodiment, the recombinant polypeptide and the cell are from the same species. In one embodiment, the amino acid sequence of the recombinant polypeptide is identical or substantially identical to the polypeptide encoded by the endogenous genome of the cell, or differs by no more than 1%, 2%, 3%, 4%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99%. In one embodiment, the recombinant polypeptide and the cell are from the same species, e.g., the recombinant polypeptide is a human polypeptide and the cell is a human cell. In one embodiment, the recombinant polypeptide and the cell are from different species, e.g., the recombinant polypeptide is a human polypeptide and the cell is a non-human, e.g., rodent, e.g., CHO, other mammalian cells, insect cells, plants, fungi, or bacterial cells. In one embodiment, the recombinant polypeptide is exogenous to the cell, in other words, the cell is from a first species and the recombinant polypeptide is from a second species. In one embodiment, the polypeptide is a synthetic polypeptide. In one embodiment, the polypeptide is derived from a non-naturally occurring source. In one embodiment, the recombinant polypeptide is a human polypeptide or protein whose amino acid sequence differs from a naturally occurring or non-naturally occurring isoform of the human polypeptide or protein.In one embodiment, the recombinant polypeptide differs from a naturally occurring or non-naturally occurring isoform of a human polypeptide or protein by no more than 1, 2, 3, 4, 5, 10, 15, or 20 amino acid residues. In one embodiment, the recombinant polypeptide differs from a naturally occurring isoform of a human polypeptide by no more than 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, or 15% of its amino acid residues. In an embodiment in which a portion of the recombinant polypeptide comprises a sequence derived from a portion of a naturally occurring or non-natural isoform of a human polypeptide, the portion of the recombinant polypeptide differs from the corresponding portion of the naturally occurring or non-natural isoform by no more than 1, 2, 3, 4, 5, 10, 15, or 20 of its amino acid residues, or by no more than 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, or 15% of its amino acid residues.

[0043] Oxygenation level and oxygenation level are used interchangeably and as used herein refer to the level of dissolved oxygen in a volume of liquid or gas, for example in a culture. Oxygenation level can be described, for example, in units of dissolved oxygen tension (DOT), in terms of percentage of air saturation (e.g., percentage of oxygen level in air).

[0044] Production culture, as used herein, refers to a mixture of growth medium and cells (e.g., at least one cell), e.g., recombinant cells, e.g., recombinant host cells expressing a product, e.g., proteins (e.g., recombinant polypeptides), cellular factors, e.g., enzymes, and metabolic products. In certain embodiments, the production culture progresses through one or more culture phases (e.g., continuous and / or overlapping culture phases) that include cell growth / division characteristics. In certain embodiments, the processing of the production culture varies as described herein as the production culture goes through different stages. Production phase, as used herein, refers to a phase of the production culture that begins at the time of inoculation and ends when a particular criterion is reached (e.g., end of process or period, e.g., 10-30 days, e.g., 15-20 days) or when a particular cell viability criterion is reached (e.g., 90, 80, 70, 60, 50, 40, 30, 20, or 10% viability, e.g., less than 50% viability). The production phase may include an exponential growth phase, in which cell growth and / or division is exponential. The production phase may include a post-growth phase following an exponential growth phase, where cell growth and / or division is in the linear phase of the growth curve, e.g., the rate of cell growth and / or division is reduced compared to the exponential growth phase. In certain embodiments, completion of the production phase produces a production mixture from the production culture. In certain embodiments, separation of cells from the production supernatant, e.g., harvesting, as well as further separation or purification steps, e.g., post-harvesting steps, are steps following the end of the production phase.

[0045] As used herein, a production mixture refers to a mixture of a product, e.g., a recombinant polypeptide, a growth medium, and a cell (e.g., at least one cell), e.g., a recombinant cell, e.g., a recombinant host cell, capable of expressing the product. A production cell is a recombinant host cell capable of expressing a product, e.g., a recombinant polypeptide.

[0046] As used herein, operably coupled describes the relationship between the containers. In one embodiment, culture medium or production culture can be transferred between the operably coupled containers. In one embodiment, the flow of culture between the operably coupled containers occurs in a controlled manner, for example, using pumps, filters, sensors, means for maintaining or changing culture conditions, and / or means for monitoring liquid flow.

[0047] As used herein, operably linked describes the relationship between a first nucleic acid sequence, e.g., a promoter or enhancer sequence, and a second nucleic acid sequence, e.g., a protein-coding sequence, where the first nucleic acid sequence can affect the second nucleic acid sequence, e.g., by affecting transcription, epigenetic modification, and / or chromosomal topology. In an embodiment, operably linked means that the two nucleic acid sequences are contained on the same nucleic acid molecule. In a further embodiment, operably linked can further mean that the two nucleic acid sequences are adjacent to each other on the same nucleic acid molecule, e.g., within 1000, 500, 100, 50, or 10 base pairs of each other, or directly adjacent to each other. In an embodiment, a promoter or enhancer sequence operably linked to a protein-coding sequence can promote transcription of the protein-coding sequence, e.g., in a cell or cell-free system capable of performing transcription.

[0048] In certain embodiments, the methods of the present disclosure can or include bioreactors in which the production culture, cells of the production culture, or supernatant from the production culture are maintained at different temperatures throughout the different phases. 培養 As used herein, T is the temperature at which the cells of a production culture are grown, e.g., in a growth medium, from the start of inoculation to the end of the production phase to produce a production culture in which a protein is produced. In certain embodiments, T 培養 The temperature ranges from 30℃ to 38℃. 産生As used herein, T is the initial temperature to which the production culture is cooled after the post-exponential growth phase. 産生 is 35°C, 34°C, 33°C, 32°C, 31°C, or 30°C, for example, 30°C to less than 33°C. 採取 As used herein, T is the second temperature to which the production culture is cooled prior to harvesting (e.g., separation of the cells from the supernatant). In one embodiment, T 採取 is 29°C, 28°C, 27°C, 26°C, 25°C, 24°C, 23°C, 22°C, 21°C, 20°C, 19°C, 18°C, 17°C, 16°C, 15°C, 14°C, 13°C, 12°C, 11°C, 10°C, 9°C, 8°C, 7°C, 6°C, 5°C, or 4°C. 採取 is 12°C to 18°C, for example, 15°C. 採取 is less than 6°C, 7°C, 8°C, 9°C, 10°C, 11°C, 12°C, 13°C, 14°C, 15°C, 16°C, 17°C, 18°C, 19°C, 20°C, 21°C, 22°C, 23°C, or 24°C. 採取 is 15°C±3°C.

[0049] As used herein, Cas9 molecule or Cas9 polypeptide refers to a molecule or polypeptide that can interact with guide RNA (gRNA) molecule and coordinate with gRNA molecule to home or localize to a site that includes target domain and PAM sequence.As used herein, Cas9 molecule and Cas9 polypeptide include naturally occurring Cas9 molecule and engineered, altered or modified Cas9 molecule or Cas9 polypeptide that differs from reference sequence, e.g., most similar naturally occurring Cas9 molecule or sequence, e.g., at least one amino acid residue.Exemplary Cas9 molecule or Cas9 polypeptide sequences can be found in WO2015 / 157070, which is incorporated herein by reference in its entirety.Cas9 molecule or Cas9 polypeptide includes Cas9 molecule with DNA cleavage and nicking activity.

[0050] The disclosures of each patent, patent application, and publication cited herein are incorporated herein by reference in their entirety. Although the present invention has been disclosed with reference to certain embodiments, it is apparent that other embodiments and variations of the present invention may be devised by those skilled in the art without departing from the true spirit and scope of the present invention. It is intended that the appended claims be construed to include all such embodiments and equivalent variations.

[0051] Decreased levels of endogenous proteins The present disclosure relates, in part, to a method for producing a product, e.g., a recombinant polypeptide, in a cell, e.g., a producing cell, comprising reducing the level of one or more endogenous proteins in the cell, e.g., the producing cell. Without wishing to be bound by theory, it is believed that reducing the level of one or more endogenous proteins can improve one or more properties of the producing cell, e.g., specific production rate (qP), growth rate, product yield, and / or viable cell concentration. Endogenous proteins can consume space and / or resources (e.g., translation, post-translational processing, and secretion space / resources) in the endoplasmic reticulum or Golgi, reducing the capacity available for the producing cell to produce a product, e.g., a recombinant polypeptide. Endogenous proteins may be more redundant to each other in terms of functionality to the cell, e.g., the producing cell, or may be unnecessary for cell viability or growth in the artificial environment of biomanufacturing, e.g., bioreactors and cell cultures.

[0052] In some embodiments, reducing the level of one or more endogenous proteins in a cell, e.g., a production cell, includes reducing the level of one or more endogenous proteins by at least 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100% compared to a similar cell in which the level of one or more endogenous proteins is not reduced. In some embodiments, reducing the level of one or more endogenous proteins in a cell, e.g., a production cell, includes eliminating essentially all, e.g., all, of the one or more endogenous proteins from the cell, e.g., the production cell. The level of one or more endogenous proteins can be assessed, for example, by the methods described in Porter, AJ, et al. (2010). "Strategies for selecting recombinant CHO cell lines for cGMP manufacturing: realizing the potential in bioreactors." Biotechnol Prog 26(5):1446-1454.

[0053] In some embodiments, reducing the level of one or more endogenous proteins in a cell, such as a producing cell, improves qP. As used herein, qP refers to the production rate of a particular product. In some embodiments, qP has units of product per unit producing cell (e.g., grams or viable cell number) per unit time. In certain embodiments, the qP is improved by at least 1.05-fold (i.e., 1.05-fold), 1.06-fold, 1.07-fold, 1.08-fold, 1.09-fold, 1.1-fold, 1.12-fold, 1.13-fold, 1.14-fold, 1.15-fold, 1.16-fold, 1.17-fold, 1.18-fold, 1.19-fold, 1.2-fold, 1.25-fold, 1.3-fold, 1.35-fold, 1.4-fold, 1.45-fold, 1.5-fold, 1.55-fold, 1.6-fold, 1.65-fold, 1.7-fold, 1.75-fold, 1.8-fold, 1.85-fold, 1.9-fold, 1.95-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, or 10-fold over the qP of a similar cell, e.g., a producing cell, in which the levels of one or more endogenous proteins are not reduced. In certain embodiments, qP is improved by at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 65, or 70% compared to a similar cell, e.g., a producing cell, that does not have reduced levels of one or more endogenous proteins. qP can be assessed, for example, by quantification of secreted protein products by ELISA or quantitative chromatography (e.g., Protein A HPLC).

[0054] In certain embodiments, reducing the level of one or more endogenous proteins in a cell, eg, a production cell, improves cell growth, eg, the rate at which the cell grows and / or divides. In certain embodiments, cell growth is improved by at least 1.05 fold (i.e., 1.05-fold), 1.06-fold, 1.07-fold, 1.08-fold, 1.09-fold, 1.1-fold, 1.12-fold, 1.13-fold, 1.14-fold, 1.15-fold, 1.16-fold, 1.17-fold, 1.18-fold, 1.19-fold, 1.2-fold, 1.25-fold, 1.3-fold, 1.35-fold, 1.4-fold, 1.45-fold, 1.5-fold, 1.55-fold, 1.6-fold, 1.65-fold, 1.7-fold, 1.75-fold, 1.8-fold, 1.85-fold, 1.9-fold, 1.95-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, or 10-fold over cell growth of a similar cell, e.g., a production cell, in which the level of one or more endogenous proteins is not reduced. In certain embodiments, cell growth is improved, e.g., increased, by at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 65, or 70% compared to a similar cell, e.g., a production cell, that does not have reduced levels of one or more endogenous proteins. Cell growth can be assessed, for example, by measuring viable cell concentration over time using an automated trypan blue exclusion assay (e.g., using a Beckman coulter Vi-Cell XR).

[0055] In certain embodiments, reducing the level of one or more endogenous proteins in a cell, eg, a production cell, improves product yield, eg, the amount of product that a culture produces. In certain embodiments, cell growth is improved by at least 1.05 fold (i.e., 1.05-fold), 1.06-fold, 1.07-fold, 1.08-fold, 1.09-fold, 1.1-fold, 1.12-fold, 1.13-fold, 1.14-fold, 1.15-fold, 1.16-fold, 1.17-fold, 1.18-fold, 1.19-fold, 1.2-fold, 1.25-fold, 1.3-fold, 1.35-fold, 1.4-fold, 1.45-fold, 1.5-fold, 1.55-fold, 1.6-fold, 1.65-fold, 1.7-fold, 1.75-fold, 1.8-fold, 1.85-fold, 1.9-fold, 1.95-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, or 10-fold over product yield of a similar cell, e.g., a producing cell, in which the levels of one or more endogenous proteins are not reduced. In certain embodiments, the product yield is increased by at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 65, or 70% compared to a similar culture of a similar cell, e.g., a producing cell, in which the levels of one or more endogenous proteins are not reduced. Product yield can be assessed, for example, by quantification of secreted protein product by ELISA or by quantitative chromatography (e.g., Protein A HPLC).

[0056] In some embodiments, reducing the level of one or more endogenous proteins in a cell, such as a production cell, improves qP and cell growth. In some embodiments, reducing the level of one or more endogenous proteins in a cell, such as a production cell, improves qP and product yield. In some embodiments, reducing the level of one or more endogenous proteins in a cell, such as a production cell, improves product yield and cell growth. In some embodiments, reducing the level of one or more endogenous proteins in a cell, such as a production cell, improves qP, product yield, and cell growth.

[0057] Endogenous proteins Endogenous proteins whose levels may be reduced in the methods described herein include those that are non-essential (e.g., to cell growth and / or viability, e.g., in a biomanufacturing environment), functionally redundant with other endogenous proteins whose levels may not be reduced, and / or secreted proteins. With the disclosure herein and with minimal experimentation, one of skill in the art will be able to recognize which endogenous proteins of a cell, e.g., a CHO cell, are non-essential, redundant, and / or secreted proteins.

[0058] In some embodiments, endogenous proteins whose levels may be reduced are proteins that are expressed at least at very high levels, e.g., as determined by the method of Example 1. In some embodiments, endogenous proteins whose levels may be reduced are proteins that are expressed at least at high levels, e.g., as determined by the method of Example 1. In some embodiments, endogenous proteins whose levels may be reduced are proteins that are expressed at least at moderate levels, e.g., as determined by the method of Example 1.

[0059] In some embodiments, the endogenous protein whose level can be reduced is a protein associated with redundant, non-essential, or secretion-related functions, for example, in a protein function database, such as the PANTHER database in Example 1. In some embodiments, the endogenous protein whose level can be reduced is associated with a functional keyword listed in Table E1, or a substantially similar functional association. In some embodiments, the endogenous protein whose level can be reduced is a protein associated with immune function, disease resistance, cell communication, and / or secretion.

[0060] In an embodiment, the endogenous protein whose level may be reduced is a protein that is expressed at least at a very high level, e.g., as determined by the method of Example 1, and is associated with a function related to redundancy, non-essentiality, or secretion in a protein function database, e.g., the PANTHER database of Example 1, e.g., associated with a keyword in Table E1. In an embodiment, the endogenous protein whose level may be reduced is a protein that is expressed at least at a high level, e.g., as determined by the method of Example 1, and is associated with a function related to redundancy, non-essentiality, or secretion in a protein function database, e.g., the PANTHER database of Example 1, e.g., associated with a keyword in Table E1. In an embodiment, the endogenous protein whose level may be reduced is a protein that is expressed at least at a moderate level, e.g., as determined by the method of Example 1, and is associated with a function related to redundancy, non-essentiality, or secretion in a protein function database, e.g., the PANTHER database of Example 1, e.g., associated with a keyword in Table E1.

[0061] In some embodiments, the endogenous protein whose level can be reduced is not a protein associated with an essential function, such as a function important or critical for cell growth, viability, or product production. In some embodiments, the endogenous protein whose level can be reduced is not a protein associated with an essential function, for example, in a protein function database, such as the PANTHER database in Example 1. In some embodiments, the endogenous protein whose level can be reduced is not associated with a functional keyword listed in Table E2, or a substantially similar functional association. In some embodiments, the endogenous protein whose level can be reduced is not a protein associated with cell metabolism, mitochondrial function, cell structure, DNA replication, cell division, checkpoint inhibition / passage, transcription, translation, post-translational modification, protein folding, or heat shock response.

[0062] Exemplary endogenous proteins (and / or genes encoding said endogenous proteins) whose levels may be reduced are listed in Table E5.

[0063] In some embodiments, the methods disclosed herein include reducing the level of more than one endogenous protein. In some embodiments, the methods disclosed herein include reducing the level of one, two, three, four, five, six, seven, eight, nine, ten, or more (e.g., twenty or more) endogenous proteins (and optionally up to 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, or 2 endogenous proteins). In some embodiments, the methods disclosed herein include reducing the level of two or three endogenous proteins, for example, a combination of endogenous proteins selected from the combinations in Table E6. In certain embodiments, the methods disclosed herein include reducing the levels of a combination of two or three endogenous proteins, e.g., endogenous proteins selected from those listed in Table E5.

[0064] Methods for reducing levels of endogenous proteins The present disclosure is directed, in part, to a method for producing a product, e.g., a recombinant polypeptide, in a cell, e.g., a production cell, comprising reducing the level of one or more endogenous proteins in the cell, e.g., the production cell. In an embodiment, reducing the level of an endogenous protein in a cell, e.g., a production cell, comprises removing, e.g., knocking out, a copy of a gene encoding the endogenous protein. In an embodiment, reducing the level of an endogenous protein in a cell, e.g., a production cell, comprises removing, e.g., knocking out, all (e.g., both) copies of the gene encoding the endogenous protein from the genome of the cell. In an embodiment, reducing the level of an endogenous protein in a cell, e.g., a production cell, comprises removing, e.g., knocking out, a regulatory nucleic acid sequence, e.g., a promoter or enhancer, operably linked to the gene encoding the endogenous protein. In an embodiment, reducing the level of an endogenous protein in a cell, e.g., a production cell, comprises removing, e.g., knocking out, all (e.g., both) copies of a regulatory nucleic acid sequence, e.g., a promoter or enhancer, operably linked to the gene encoding the endogenous protein.

[0065] In some embodiments, for example, eliminating the knockout comprises introducing a deletion, substitution, or insertion mutation into the gene encoding the endogenous protein, or into a regulatory nucleic acid sequence, such as a promoter or enhancer, operably linked to the gene encoding the endogenous protein, such as a mutation that reduces the expression level of the endogenous protein.In some embodiments, for example, eliminating the knockout comprises introducing a deletion or insertion of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more base pairs into the gene encoding the endogenous protein, or into a regulatory nucleic acid sequence, such as a promoter or enhancer, operably linked to the gene encoding the endogenous protein. In an embodiment, for example, eliminating the knockout includes substituting one, two, three, four, five, six, seven, eight, nine, ten, or more base pairs (e.g., a transition or transversion mutation) for a different base pair in the gene encoding the endogenous protein or in a regulatory nucleic acid sequence, e.g., a promoter or enhancer, operably linked to the gene encoding the endogenous protein.

[0066] For example, an insertion mutation that disrupts the reading frame of a gene encoding an endogenous protein, or a substitution mutation that changes the start codon of a gene encoding an endogenous protein, would both be examples of removals, e.g., knockouts, that reduce the level of an endogenous protein. As a further example, for example, eliminating the knockout may include the insertion of a marker (e.g., an antibiotic resistance, a auxotrophic relief, or a fluorescent marker coding gene) in a manner that deletes a promoter or a portion of a promoter operably linked to the gene encoding the endogenous protein. In certain embodiments, for example, eliminating the knockout results in a complete loss of endogenous protein production from a copy of the gene encoding the endogenous protein. In other embodiments, for example, eliminating the knockout results in lower levels of production of the endogenous protein, e.g., a functional endogenous protein. In other embodiments, for example, eliminating the knockout results in the production of a variant of the endogenous protein that is truncated, less functional, non-functional, misfolded, and / or prone to degradation.

[0067] Removing, for example, knocking out, the copy of the gene encoding the endogenous protein or the regulatory element operably linked to said gene can be achieved by any gene editing system known in the art.Exemplary gene editing systems include clustered regulatory interspaced short palindromic repeats (CRISPR) system, zinc finger nuclease (ZFN), and transcription activator-like effector-based nuclease (TALEN).ZFN, TALEN, and CRISPR-based methods are described, for example, in Gaj et al., Trends Biotechnol.31.7(2013):397-405, and CRISPR methods of gene editing are described, for example, in Guan et al., Application of CRISPR-Cas system in gene therapy.Preclinical progress in animal models. DNA Repair 2016 July 30 [Epub ahead of print]; Zheng et al., Precise gene deletion and replacement using the CRISPR / Cas9 system in human cells. BioTechniques, Vol. 57, No. 3, September 2014, pp. 115-124. Those skilled in the art will recognize these and other options for editing the genome (e.g., knocking out genes) in cells, e.g., production cells.

[0068] In an embodiment, for example, knocking out a copy of an endogenous protein-encoding gene or a regulatory element operably linked to said gene comprises using a CRISPR-Cas9 molecule, e.g., a Cas9 molecule, in combination with a regulatory nucleic acid sequence, e.g., a promoter or enhancer-specific RNA (e.g., gRNA, sgRNA, and / or tracrRNA), operably linked to the endogenous protein-encoding gene or to the endogenous protein-encoding gene.

[0069] In some embodiments, reducing the level of endogenous protein in a cell, for example a production cell, comprises reducing, for example, knocking down, the level of the mRNA transcript that codes for the endogenous protein in the cell. In some embodiments, reducing, for example, knocking down, the level of the mRNA transcript that codes for the endogenous protein comprises, for example, using siRNA that can bind to the nucleic acid, for example, mRNA, that codes for the endogenous protein, or the regulatory nucleic acid sequence, for example, promoter or enhancer, operably linked thereto. Those skilled in the art will recognize the tools and techniques for designing and delivering siRNA to cells. Such tools and / or techniques include, but are not limited to, the following: Dharmacon Horizon siDesign tool, InvivoGen siRNA Wizard, GenScript siRNA Construct Services, IDT Custom Dicer-Substrate siRNA, Sigma-Aldrich siRNA Design Service, or the method taught by www.rnaiweb.com / RNAi / siRNA_Design / . In certain embodiments, reducing, e.g., knocking down, the level of an mRNA transcript encoding an endogenous protein results in at least a 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100% reduction in the level of an mRNA transcript encoding an endogenous protein in a cell.

[0070] product Provided herein are cells, cells or cell lines, and methods for producing high yields of products by reducing the level of endogenous proteins in cells, e.g., producing cells, cells or cell lines, and / or compositions for improving the quality of products (e.g., increasing the level of products, e.g., recombinant polypeptides, produced). The products described herein include polypeptides, e.g., recombinant proteins, multimeric proteins or complexes, lipid-encapsulated particles, e.g., virus-like particles, vesicles, or exosomes, or other molecules. In one embodiment, the product is a polypeptide, e.g., a recombinant polypeptide. In one embodiment, the product is an exosome. For example, the recombinant polypeptide may be a protein that is difficult to express, or a complex and / or a protein with a non-native structure, e.g., a next-generation biological protein, e.g., a bispecific antibody molecule, a fusion protein, or a glycosylated protein.

[0071] In embodiments, the cells or cell lines produced by the methods or compositions described herein produce products, such as recombinant polypeptides, that are useful for treating medical conditions, disorders, or diseases. Examples of medical conditions, disorders, or diseases include, but are not limited to, metabolic diseases or disorders (e.g., metabolic enzyme deficiencies), endocrine disorders (e.g., hormone deficiencies), hemostatic disorders, thrombosis, hematopoietic disorders, pulmonary disorders, gastrointestinal disorders, autoimmune diseases, immune disorders (e.g., immunodeficiencies), infertility, transplantation, cancer, and infectious diseases.

[0072] In an embodiment, the product is an exogenous protein, for example a protein that is not naturally expressed by the cell. In one embodiment, the protein is from one species and the cell is from a different species. In another embodiment, the protein is a non-naturally occurring protein.

[0073] In other embodiments, the product is a protein that is endogenously expressed by the cell. In one embodiment, the product is a protein that is endogenously expressed by the cell at endogenous or natural levels. The methods and compositions described herein are used to increase the production and quality of an endogenous product, e.g., a naturally occurring product that is naturally produced by the cell. In another embodiment, an exogenous nucleic acid that encodes a product, e.g., a protein, is introduced into the cell and expressed by the cell. In another embodiment, an exogenous nucleic acid is introduced into the cell that increases the expression of a product that is endogenously expressed by the cell. By way of example, the exogenous nucleic acid includes a sequence that activates a promoter that controls the expression of an endogenous product of the cell.

[0074] The recombinant product may be, for example, a therapeutic or diagnostic product, useful for drug screening. Therapeutic or diagnostic products include, but are not limited to, antibody molecules, e.g., antibodies or antibody fragments, fusion proteins, hormones, cytokines, growth factors, enzymes, glycoproteins, lipoproteins, reporter proteins, therapeutic peptides, or structural and / or functional fragments or hybrids of any of these. In other embodiments, the therapeutic or diagnostic product is a synthetic polypeptide, e.g., the entire polypeptide or a portion thereof is not derived from or has any sequence or structural similarity to any naturally occurring polypeptide, e.g., the naturally occurring polypeptides described above.

[0075] In one embodiment, the recombinant product is an antibody molecule. In one embodiment, the recombinant product is a therapeutic antibody molecule. In another embodiment, the recombinant product is a diagnostic antibody molecule, e.g., a monoclonal antibody useful in imaging techniques or diagnostic tests.

[0076] An antibody molecule, as used herein, is a protein or polypeptide sequence derived from an immunoglobulin molecule that specifically binds to an antigen. In one embodiment, the antibody molecule is a full-length antibody or an antibody fragment. The antibodies and multiformat proteins may be polyclonal or monoclonal, multiple or single chain, or intact immunoglobulins, and may be derived from natural or recombinant sources. The antibody may be a tetramer of immunoglobulin molecules. In one embodiment, the antibody is a monoclonal antibody. The antibody may be a human antibody or a humanized antibody. In one embodiment, the antibody is an IgA, IgG, IgD, or IgE antibody. In one embodiment, the antibody is an IgG1, IgG2, IgG3, or IgG4 antibody.

[0077] "Antibody fragment" refers to at least a portion of an intact antibody or a recombinant variant thereof, and refers to an antigen-binding domain, e.g., an antigen-determining variable region of an intact antibody, sufficient to confer recognition and specific binding of the antibody fragment to a target, e.g., an antigen. Examples of antibody fragments include, but are not limited to, Fab, Fab', F(ab')2, and Fv fragments, scFv antibody fragments, linear antibodies, single domain antibodies (either VL or VH) such as sdAbs, camelid VHH domains, and multispecific antibodies formed from antibody fragments, e.g., bivalent fragments comprising two Fab fragments linked by a disulfide bridge at the hinge region, and isolated CDRs or other epitope-binding fragments of antibodies. Antigen-binding fragments can also be incorporated into single domain antibodies, maxibodies, minibodies, nanobodies, intrabodies, diabodies, triabodies, tetrabodies, v-NARs and bis-scFvs (see, e.g., Hollinger and Hudson, Nature Biotechnology 23:1126-1136, 2005). Antigen-binding fragments can also be grafted onto scaffolds based on polypeptides such as fibronectin type III (Fn3) (see U.S. Patent No. 6,703,199, which describes fibronectin polypeptide minibodies).

[0078] In an embodiment, the polypeptide is, for example, Botox, Myoblock, Neuroblock, Dysport (or other serotypes of botulinum neurotoxin), alglucosidase alfa, daptomycin, YH-16, choriogonadotropin alfa, filgrastim, cetrorelix, interleukin-2, aldesleukin, teceleukin, denileukin diftitox, interferon alfa-n3 (injection), interferon alfa-nl, DL-8234, interferon, Suntory (gamma-1a), interferon Gamma, Thymosin alpha 1, Tasonermin, Zygifab, Biperatab, Etitab, Clofab, Nesiritide, Abatacept, Alefacept, Rebif, Eptoterminalfa, Teriparatide, Calcitonin, Etanercept, Hemoglobin glutamate 250 (bovine), Drotrecogin alfa, Collagenase, Carperitide, Recombinant human epidermal growth factor, DWP401, Darbepoetin alfa, Epoetin omega, Epoetin beta, Epoetin alfa, Desirudin, Lepirudin, Bivalirudin, Nonacog alfa, Mononin, Eptacog alf α (activated), recombinant factor VIII + VWF, recombinant, recombinant factor VIII, factor VIII (recombinant), alfumato, octocog alfa, factor VIII, palifermin, indikinase, tenecteprase, alteprase, pamiteprase, leteprase, nateprase, monteprase, follitropin alfa, rFSH, hpFSH, micafungin, pegfilgrastim, lenograstim, nartograstim, sermorelin, glucagon, exenatide, pramlintide, iniglucerase, galsulfase, leukotropin, Molgramostelin, Triptorelin acetate, Histrelin (Hydron), Deslorelin, Histrelin, Nafarelin, Leuprolide (ATRIGEL), Leuprolide (DUROS), Goserelin, Eutropin, Somatropin, Mecasermin, Enulfavirtide, Org-33408, Insulin glargine, Insulin glulisine, Insulin (inhaled), Insulin lispro, Insulin deternil, Insulin (RapidMist), Mecasermin linfavert, Anakinra, Sermoleukin, 99mTc-Apsitide, Myelopid,Betaseron, glatiramer acetate, gepon, sargramostim, oprelvekin, human leukocyte-derived alpha interferon, viribe, insulin (recombinant), recombinant human insulin, insulin aspart, mechasenin, roferon-A, interferon alpha 2, alphaferon, interferon alpha-1, interferon alpha, avonex recombinant human luteinizing hormone, dornase alpha, trafermin, ziconotide, taltirelin, diboterminalfa, atosiban, becaplermin, eptifibatide, zemaila , CTC-111, Shambac-B, Octreotide, Lanreotide, Ancestilin, Agalsidase beta, Agalsidase alfa, Laronidase, Prezatide copper acetate, Rasburicase, Ranibizumab, Actimmune, PEG-Intron, Tricomin, Recombinant human thyroid hormone (PTH) 1-84, Epoetin delta, Transgenic antithrombin III, Granditropin, Vitrase, Recombinant insulin, Interferon alfa, GEM-21S, Vapreotide, Idursulfase, Omnapatrilat, Recombinant Serum albumin, certolitumab pegol, glucaridase, human recombinant C1 esterase inhibitor, lanoteplase, recombinant human growth hormone, enfuvirtide, VGV-1, interferon (alpha), lucinactant, aviptadil, icatibant, ecalcantide, omiganan, aurograv, pexiganan acetate, ADI-PEG-20, LDI-200, degarelix, syntredelin besudotox, favd, MDX-1379, ISAtx-247, liraglutide, teriparatide, tifacogin, AA4500, T4N5 liposomal lotion, catumaxomab, DWP413, ART-123, chrysalin, desmotheplacen, ameziplacen, colforlitropinalfa, TH-9507, teduglutide, diamide, DWP-412, growth hormone, recombinant G-CSF, insulin, insulin (Technosphere), insulin (AERx), RGN-303, DiaPep277, interferon beta, interferon alpha-n3, belatacept, transdermal insulin patch, AMG-531, MBP-8298, xerecept, opevacan, AIDSVAX,GV-1001, Lymphoscan, Lampirinase, Kupoxisan, Ruspritide, MP52, Sipuleucel-T, CTP-37, Insegia, Vitespen, Human Thrombin, Thrombin, TransMID, Alfimeprase, Precase, Terlipressin, EUR-1008M, Recombinant FGF-I, BDM-E, Rotigaptide, ETC-216, P-113, MBI-594AN, Duramycin, SCV-07, OPI -45, endostatin, angiostatin, ABT-510, Bowman-Birk inhibitor, XMP-629, 99mTc-HYNIC-annexin V, kahalalide F, CTCE-9908, teverelix, ozarelix, lornideptin, BAY-504798, interleukin 4, PRX-321, pepscan, ivoctadequin, lactoferrin, TRU-015, IL-21, ATN-161, cilengitide, albuferon, bifasix, IRX-2, omega interferon, PCK-3145, CAP-232, pasireotide, huN901-DMI, SB-249553, Oncovax-CL, Oncovax-P, BLP-25, Delvax-16, MART-1, gp100, tyrosinase, nemifitide, rAAT, CGRP, pegsnercept, thymosin beta 4, plitidepsi , GTP-200, ramoplanin, GRASPA, OBI-1, AC-100, salmon calcitonin (Eligen), kusamorelin, capromorelin, Caldeva, bellafermin, 131I-TM-601, KK-220, T-10, ularitide, depelestat, hematide, chrysalin, rNAPc2, recombinant factor V111 (PEGylated liposome), bFGF, PEGylated recombinant staphylokinase, V-10153, sonolysis Prolyse, Neurovax, CZEN-002, rGLP-1, BIM-51077, LY-548806, Exenatide (controlled release Medisorb), AVE-0010, GA-GCB, Avorelin, ACM-9604, Linaclotide acetate, CETi-1, Homospan, VAL, Rapid-acting insulin (injectable, Viadel), Insulin (Eligen), Recombinant methionyl human leptin, Pitrakinra, Maltikin, RG-1068, MM-093, NBI-6024,AT-001, PI-0824, Org-39141, Cpn10, Lactoferrin, rEV-131, rEV-131, recombinant human insulin, RPI-78M, oplevekin, CYT-99007 CTLA4-Ig, DTY-001, Balategrast, Interferon alfa-n3, IRX-3, RDP-58, Tauferon, Bile salt-stimulated lipase, Melispase, Araline phosphatase, EP-2104R, Melnotan-II, Bremelanotide, ATL-104, recombinant human microplasmin, AX-200, SEMAX, ACV-1, Xen-2174, CJC-1008, Dynorphin A, SI-6603, LAB GHRH, AER-002, BGC-728, ALTU-135, recombinant neuraminidase, Vacc-5q, Vacc-4x, Tat toxoid, YSPSL, CHS-13340, PTH(1-34)(Novasam), Ostabolin-C, PTH analogue, MBRI-93.02, MTB72F, MVA-Ag85A, FARA04, BA-210, recombinant plague FIV, AG-702, OxSODrol, rBetV1, Der-p1 / Der-p2 / Der-p7, PR1 peptide antigen, mutant ras vaccine, HPV-16 E7 lipopeptide vaccine, Labyrinth-in, WT1-peptide, IDD-5, CDX-110, Pentrise, Norelin, CytoFab, P-9808, VT-111, Icrocaptide, Telbermin, Rupintrivir, Reticulose, rGRF, HA, alpha-galactosidase A, ACE-011, ALTU-140, CGX-1160, angiotensin, D-4F, ETC-642, APP-018, rhMBL, SCV-0 7, DRF-7295, ABT-828, ErbB2-specific immunotoxin, DT3SSIL-3, TST-10088, PRO-1762, Combotox, cholecystokinin-B / gastrin-receptor binding peptide, 111In-hEGF, AE-37, trastuzumab-DM1, antagonist G, IL-12, PM-02734, IMP-321, rhIGF-BP3, BLX-883, CUV-1647, L-19 Basedra (based ra), Re-188-P-2045, AMG-386, DC / 1540 / KLH, VX-001, AVE-9633, AC-9301,NY-ESO-1 (peptide), NA17.A2 peptide, CBP-501, recombinant human lactoferrin, FX-06, AP-214, WAP-8294A, ACP-HIP, SUN-11031, peptide YY[3-36], FGLL, atacicept, BR3-Fc, BN-003, BA-058, human parathyroid hormone 1-34, F-18-CCR1, AT-1100, JPD-003, PTH(7-34) (Novasum) , duramycin, CAB-2, CTCE-0214, glycoPEGylated erythropoietin, EPO-Fc, CNTO-528, AMG-114, JR-013, factor XIII, aminocandin, PN-951, 716155, SUN-E7001, TH-0318, BAY-73-7977, teverelix, EP-51216, hGH, OGP-I, sifvirtide, TV4710, ALG-889, Org-41259, rh CC10, F-991, thymopentin, r(m)CRP, liver-selective insulin, subarin, L19-IL-2 fusion protein, elafin, NMK-150, ALTU-139, EN-122004, rhTPO, thrombopoietin receptor agonist, AL-108, AL-208, nerve growth factor antagonist, SLV-317, CGX-1007, INNO-105, teriparatide (Eligen), GEM-OS1, AC-162352, PR X-302, LFn-p24 fusion, EP-1043, gpE1, gpE2, MF-59, hPTH(1-34), 768974, SYN-101, PGN-0052, Abysscumin, BIM-23190, multi-epitope tyrosinase peptide, encastim, APC-8024, GI-5005, ACC-001, TTS-CD3, vascular targeting TNF, desmopressin, onercept, and TP-9201.

[0079] In certain embodiments, the polypeptide is adalimumab (Humira), infliximab (Remicade™), rituximab (Rituxan™ / MabThera™), etanercept (ENBREL™), bevacizumab (Avastin™), trastuzumab (Herceptin™), pegligrastim (Neulasta™), or any other suitable polypeptide, including biosimilars and biobetters.

[0080] Other suitable polypeptides are those listed below and in Table 1 of US Application Publication No. 2016 / 0097074. [Table 1] TIFF2024161560000003.tif213149 TIFF2024161560000004.tif206149 TIFF2024161560000005.tif213149 TIFF2024161560000006.tif46149

[0081] In embodiments, the polypeptide is a hormone, blood clotting / clotting factor, cytokine / growth factor, antibody molecule, fusion protein, protein vaccine, or peptide shown in Table 2.

[0082] Exemplary recombinant products that can be produced using the methods described herein include, but are not limited to, those provided in the table below.

[0083] [Table 2] TIFF2024161560000008.tif115149 TIFF2024161560000009.tif203149

[0084] In an embodiment, the protein is a multispecific protein, such as a bispecific antibody as shown in Table 3.

[0085] [Table 3] TIFF2024161560000011.tif221149 TIFF2024161560000012.tif216149 TIFF2024161560000013.tif216149 TIFF2024161560000014.tif221149 TIFF2024161560000015.tif74149

[0086] In an embodiment, the product is a polypeptide listed in Table 4.

[0087] [Table 4] TIFF2024161560000017.tif219149 TIFF2024161560000018.tif222149 TIFF2024161560000019.tif215149 TIFF2024161560000020.tif88149

[0088] In some embodiments, the polypeptide is an antigen expressed by a cancer cell. In some embodiments, the recombinant or therapeutic polypeptide is a tumor-associated or tumor-specific antigen. In some embodiments, the recombinant or therapeutic polypeptide is an antigen selected from the group consisting of HER2, CD20, 9-O-acetyl-GD3, βhCG, A33 antigen, CA19-9 marker, CA-125 marker, caleticulin, carbonic anhydrase IX (MN / CA IX), CCR5, CCR8, CD19, CD22, CD25, CD27, CD30, CD33, CD38, CD44v6, CD63, CD70, CC123, CD138, carcinoembryonic antigen (CEA; CD66e), desmoghrelin 4, E-cadherin neoepitope, endosialin, ephrin A2 (EphA2), epidermal growth factor receptor (EGFR), epithelial cell adhesion molecule (EpCAM), ErbB2, fetal acetonidase (EA), and the like. Chiral receptor, fibroblast activation antigen (FAP), fucosyl GM1, GD2, GD3, GM2, ganglioside GD3, globo H, glycoprotein 100, HER2 / neu, HER3, HER4, insulin-like growth factor receptor 1, Lewis-Y, LG, Ly-6, melanoma-specific chondroitin sulfate proteoglycan (MCSCP), mesothelin, MUCl, MUC2, MUC3, MUC4, MUC5 AC , MUC5 B , MUC7, MUC16, Mullerian inhibitory substance (MIS) receptor type II, plasma cell antigen, polySA, PSCA, PSMA, sonic hedgehog (SHH), SAS, STEAP, sTn antigen, TNF-α precursor, and combinations thereof.

[0089] In certain embodiments, the polypeptide is an activating receptor, such as 2B4 (CD244), alpha4beta1 integrin, beta2 integrin, CD2, CD16, CD27, CD38, CD96, CD100, CD160, CD137, CEACAMl (CD66), CRTAM, CSl (CD319), DNAM-1 (CD226), GITR (TNFRSF18), the activating form of KIR, NKG2C, NKG2D, NKG2E , one or more natural cytotoxic receptors, NTB-A, PEN-5, and combinations thereof; optionally the β2 integrin comprises CD11a-CD18, CD11b-CD18, or CD11c-CD18; optionally the activating form of KIR comprises KIR2DS1, KIR2DS4, or KIR-S; and optionally the natural cytotoxic receptor comprises NKp30, NKp44, NKp46, or NKp80.

[0090] In certain embodiments, the polypeptide is an inhibitory receptor and is selected from an inhibitory form of KIR, ILT2 / LIR-1 / CD85j, KIR, KLRG1, LAIR-1, NKG2A, NKR-P1A, Siglec-3, Siglec-7, Siglec-9, and combinations thereof, optionally wherein the inhibitory form of KIR includes KIR2DL1, KIR2DL2, KIR2DL3, KIR3DL1, KIR3DL2, or KIR-L.

[0091] In one embodiment, the polypeptide is an activating receptor and is selected from the group consisting of CD3, CD2 (LFA2, OX34), CD5, CD27 (TNFRSF7), CD28, CD30 (TNFRSF8), CD40L, CD84 (SLAMF5), CD137 (4-1BB), CD226, CD229 (Ly9, SLAMF3), CD244 (2B4, SLAMF4), CD319 (CRACC, BLAME), CD352 ( Lyl08, NTBA, SLAMF6), CRTAM (CD355), DR3 (TNFRSF25), GITR (CD357), HVEM (CD270), ICOS, LIGHT, LTβR (TNFRSF3), OX40 (CD134), NKG2D, SLAM (CD150, SLAMF1), TCRα, TCRβ, TCRδγ, TIM1 (HAVCR, KIM1), and combinations thereof.

[0092] In one embodiment, the polypeptide is an inhibitory receptor and is selected from PD-1 (CD279), 2B4 (CD244, SLAMF4), B71 (CD80), B7Hl (CD274, PD-L1), BTLA (CD272), CD160 (BY55, NK28), CD352 (Ly108, NTBA, SLAMF6), CD358 (DR6), CTLA-4 (CD152), LAG3, LAIR1, PD-1H (VISTA), TIGIT (VSIG9, VSTM3), TIM2 (TIMD2), TIM3 (HAVCR2, KIM3), and combinations thereof.

[0093] Other exemplary proteins include, but are not limited to, any of the proteins listed in Tables 1-10 of Leader et al., "Protein therapeutics: a summary and pharmacological classification," Nature Reviews Drug Discovery, 2008, 7:21-39 (incorporated herein by reference), or any conjugate, variant, analog, or functional fragment of the recombinant polypeptides described herein.

[0094] Other recombinant protein products include, but are not limited to, non-antibody scaffolds or alternative protein scaffolds, such as DARPins, affibodies, and adnectins, which can be engineered to recognize or bind to one or more than one, e.g., one, two, three, four, or five or more, different targets or antigens.

[0095] In one embodiment, a vector comprising a nucleic acid sequence encoding a product, e.g., a polypeptide, e.g., a recombinant polypeptide, described herein, further comprises a nucleic acid sequence encoding a selection marker. In one embodiment, the selection marker comprises glutamine synthetase (GS), dihydrofolate reductase (DHFR), e.g., an enzyme conferring resistance to methotrexate (MTX), proline, or an antibiotic marker, e.g., an enzyme conferring resistance to antibiotics such as hygromycin, neomycin (G418), zeocin, puromycin, or blastidine. In another embodiment, the selection marker comprises or is compatible with the Selexis selection system (e.g., SUREtechnology Platform™ and Selexis Genetic Elements™ commercially available from Selexis SA) or Catalant Biologics GPEx® cell line development technology.

[0096] In one embodiment, a vector comprising a nucleic acid sequence encoding a recombinant product described herein comprises a selection marker useful for identifying a cell or cell(s) comprising a nucleic acid encoding a recombinant product described herein. In another embodiment, the selection marker is useful for identifying one or more cells comprising integration of a nucleic acid sequence encoding a recombinant product into their genome as described herein. Identification of one or more cells or cell(s) that have integrated a nucleic acid sequence encoding a recombinant protein can be useful for selecting and engineering cells or cell lines that stably express the product.

[0097] In one embodiment, the product differs from Tables 1-4 by no more than 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, or 50 amino acid residues. In another embodiment, the product differs from Tables 2 or 3 by no more than 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, or 15% of its amino acid residues. Methods for determining percent identity are discussed above.

[0098] Other recombinant products include, but are not limited to, non-antibody scaffolds or alternative protein scaffolds, such as DARPins, affibodies, and adnectins.

[0099] Other exemplary therapeutic or diagnostic proteins include, but are not limited to, the proteins listed in Tables 1-10 of Leader et al., "Protein therapeutics: a summary and pharmacological classification", Nature Reviews Drug Discovery, 2008, 7:21-39, and Walsh, "Biopharmaceutical benchmarks 2014", Nature Biotechnology, 2014, 32:992-1000, each of which is incorporated herein by reference, or any conjugate, variant, analog, or functional fragment of the recombinant polypeptides described herein.

[0100] Production Applications The methods and cells or cell lines disclosed herein can be used to evaluate different cell lines for producing different products, or to evaluate the production of different cell lines for use in bioreactors or processing vessels or tanks, or more generally for use in any source. The devices, facilities, and methods described herein are suitable for culturing any desired cell line, including prokaryotic and / or eukaryotic cell lines. Furthermore, in embodiments, the devices, facilities, and methods are suitable for culturing suspension cells or anchorage-dependent (adherent) cells, and are suitable for production operations configured for the production of polypeptide products or cells, and / or pharmaceutical and herbal products, such as those used in cell therapy and / or viral therapy.

[0101] As mentioned, in embodiments, the devices, facilities, and methods allow for the production of eukaryotic cells, e.g., mammalian cells or lower eukaryotic cells, e.g., yeast cells or filamentous fungal cells, or prokaryotic cells, e.g., gram-positive or gram-negative cells, and / or eukaryotic or prokaryotic products, e.g., proteins, peptides, antibiotics, amino acids, synthesized by eukaryotic cells on a large scale. Unless otherwise stated herein, the devices, facilities, and methods can include any desired capacity or production capacity, including, but not limited to, bench scale, pilot scale, and full production scale capacity.

[0102] Further, unless otherwise specified herein, the devices, equipment, and methods may include any suitable reactor(s), including, but not limited to, stirred tank, airlift, fiber, microfiber, hollow fiber, ceramic matrix, fluidized bed, fixed bed, and / or spouted bed bioreactors. As used herein, a "reactor" or "bioreactor" may include a fermenter or fermentation unit, or any other reaction vessel, and the terms "reactor" and "bioreactor" are used interchangeably with "fermenter". For example, in some embodiments, a bioreactor unit may perform one or more, or all of the following: feeding of nutrients and / or carbon sources, injection of a suitable gas (e.g., oxygen), inlet and outlet flow of fermentation or cell culture medium, separation of gas and liquid phases, maintaining temperature, maintaining oxygen and CO2 levels, maintaining pH levels, agitation (e.g., stirring), and / or cleaning / sterilization. An exemplary reactor unit, such as a fermentation unit, may include multiple reactors within the unit, e.g., the unit may have 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, or 100 or more bioreactors within each unit, and / or may include multiple units with single or multiple reactors within a facility. In various embodiments, the bioreactors may be suitable for batch, semi-fed batch, fed batch, perfusion, and / or continuous fermentation processes. Any suitable reactor diameter may be used. In embodiments, the bioreactors may have a volume of about 100 mL to about 50,000 L.Non-limiting examples include 100 mL, 250 mL, 500 mL, 750 mL, 1 liter, 2 liters, 3 liters, 4 liters, 5 liters, 6 liters, 7 liters, 8 liters, 9 liters, 10 liters, 15 liters, 20 liters, 25 liters, 30 liters, 40 liters, 50 liters, 60 liters, 70 liters, 80 liters, 90 liters, 100 liters, 150 liters, 200 liters, 250 liters, 300 liters, 350 liters, 400 liters, 450 liters, 500 liters, 550 liters, and the like. The reactors may be of a volume of 1000 liters, 600 liters, 650 liters, 700 liters, 750 liters, 800 liters, 850 liters, 900 liters, 950 liters, 1000 liters, 1500 liters, 2000 liters, 2500 liters, 3000 liters, 3500 liters, 4000 liters, 4500 liters, 5000 liters, 6000 liters, 7000 liters, 8000 liters, 9000 liters, 10,000 liters, 15,000 liters, 20,000 liters, and / or 50,000 liters. Additionally, suitable reactors may be multi-use, single-use, disposable, or non-disposable and may be formed from any suitable material, including stainless steel (e.g., 316L or any other suitable stainless steel) and metal alloys such as Inconel, plastic, and / or glass. In certain embodiments, suitable reactors may be circular, e.g., cylindrical. In certain embodiments, suitable reactors may be square, e.g., rectangular. Square reactors may, in some cases, offer advantages over round reactors, such as ease of use (e.g., loading and setup by one of ordinary skill in the art), greater mixing and uniformity of the reactor contents, and lower bed space.

[0103] In embodiments, and unless otherwise specified herein, the devices, facilities, and methods described herein for use with the method of making a preparation can include any suitable unit operation and / or equipment not otherwise specified, such as operations and / or equipment for the separation, purification, and isolation of such products. Any suitable equipment and environment can be used, such as conventional stick construction equipment, modular equipment, mobile and temporary equipment, or any other suitable construction, equipment, and / or layout. For example, in an embodiment, a modular clean room can be used. In addition, unless otherwise specified, the devices, systems, and methods described herein can be housed and / or performed in a single location or facility, or can be housed and / or performed in separate or multiple locations and / or facilities.

[0104] By way of non-limiting example, U.S. Publication Nos. 2013 / 0280797, 2012 / 0077429, 2011 / 0280797, 2009 / 0305626, and U.S. Patent Nos. 8,298,054, 7,629,167, and 5,656,491, which are incorporated by reference in their entireties herein, describe exemplary facilities, equipment, and / or systems that may be suitable.

[0105] Bioreactor setup and conditions In one embodiment, the bioreactor of the disclosure or utilized by the methods of the disclosure is a single-use bioreactor.

[0106] The single-use bioreactor may include a bioprocess vessel, a shell, at least one agitator, at least one sparger, at least one gas filter inlet port for the sparger(s) and headspace overlay, at least one fill port, at least one harvest port, at least one sample port, and at least one probe.

[0107] In one embodiment, the present disclosure is directed to a bioreactor including a bioprocess container. The bioprocess container is made of a liquid impermeable and flexible conformable material. For example, the bioprocess container can be made of a flexible film, such as a multi-layer film. In one embodiment, for example, the film is made of a polyethylene polymer, such as low density polyethylene, modified to form a hydrophilic surface. The hydrophilic surface is for contact with the cell culture in the bioreactor and improves wettability. In one embodiment, the polyethylene polymer is modified by being exposed to irradiation, light or plasma induction, or oxidation.

[0108] The bioprocess container can have a top, a bottom, and at least one sidewall therebetween. The bioprocess chamber can define a hollow housing for receiving a culture medium. The hollow housing can be sized to accommodate a 100 mL, 250 mL, 500 mL, 750 mL, 1 liter, 2 liters, 3 liters, 4 liters, 5 liters, 6 liters, 7 liters, 8 liters, 9 liters, 10 liters, 15 liters, 20 liters, 25 liters, 30 liters, 40 liters, 50 liters, 60 liters, 70 liters, 80 liters, 90 liters, 100 liters, 150 liters, 200 liters, 250 liters, 300 liters, 350 liters, 400 liters, 450 liters, 500 liters, 550 liters, 60 ...800 liters, 90 liters, 100 liters, 150 liters, 200 liters, 250 liters, 300 liters, 350 liters, 400 liters, 450 liters, 500 liters, 550 liters, 600 liters, 800 liters, In one embodiment, the container may have any suitable volume, such as 100 liters, 650 liters, 700 liters, 750 liters, 800 liters, 850 liters, 900 liters, 950 liters, 1000 liters, 1500 liters, 2000 liters, 2500 liters, 3000 liters, 3500 liters, 4000 liters, 4500 liters, 5000 liters, 6000 liters, 7000 liters, 8000 liters, 9000 liters, 10,000 liters, 15,000 liters, 20,000 liters, and / or 50,000 liters.

[0109] The bioreactor may include at least one inlet port for feeding material into the hollow enclosure of the bioprocess container. A mixing device comprising a rotatable shaft coupled to at least one agitator may extend into the hollow enclosure of the bioprocess container. In one embodiment, the rotatable shaft is foldable. For example, the rotatable shaft may include at least one impeller made of a hydrophilic polymeric material that is foldable or foldable towards the rotatable shaft.

[0110] The bioreactor may also include at least one baffle configured to extend adjacent to the sidewall of the bioprocess container in a longitudinal direction. The baffle may have a shape that extends radially inward from the sidewall by an amount sufficient to affect fluid flow within the hollow enclosure during mixing of the culture medium by the mixing device. The baffle may be collapsible and / or foldable. In one embodiment, for example, the baffle may define an inflatable fluid bladder that allows the baffle to be inflated and deflated. The baffle may be integral with the bioprocess container, meaning that the baffle is formed in a flexible shape-forming material. Alternatively, the baffle may be separate from the bioprocess container. The baffle may be configured to be positioned inside the hollow enclosure or may be positioned outside the hollow enclosure. When positioned outside the hollow enclosure, the sidewall of the bioprocess container fits around the shape of the baffle. For example, in one embodiment, the baffle may be removably attached to an outer metal shell. The bioprocess container may be positioned in the metal shell to fit around the shape of the baffle. The bioreactor, in one embodiment, can include about 2 to about 6 baffles spaced around the periphery of the hollow enclosure of the bioprocess container.

[0111] In one embodiment, the bioprocess container has a diameter and the one or more baffles extend radially inward a distance of about 3% to about 20%, such as about 5% to about 15% of the diameter of the bioprocess container.

[0112] The bioreactor may further include at least one sparger. The sparger may include, for example, a ballast sparger comprising a gas tube having a longitudinal portion and a lateral portion. The longitudinal portion may extend vertically into the hollow enclosure of the bioprocess container. On the other hand, the lateral portion may be located at the end of the longitudinal portion below the agitator. The lateral portion may define a plurality of holes for releasing gas into the culture medium contained within the bioprocess container. In one embodiment, the plurality of holes are drilled. The lateral portion may have any suitable shape. In one embodiment, the lateral portion may be configured to engage a rotatable shaft of the mixing device to stabilize the shaft. The rotatable shaft may extend through the lateral portion or may be housed within a shaft receiving member formed in the lateral portion.

[0113] In one embodiment, the bioreactor includes a first subsurface sparger and a second above-surface sparger. The holes in the subsurface sparger may be larger or smaller than the holes on the above-surface sparger. In one embodiment, the holes are drilled.

[0114] In one embodiment, the bioreactor can include at least one feed line extending into the hollow enclosure to feed fluid into the bioprocess container. The feed line can include a subsurface fluid outlet positioned adjacent to the agitator. The fluid outlet can be associated with a fluid control device that only allows fluid to flow out of the fluid outlet and prevents fluid from flowing in the reverse direction. For example, the fluid control device can include a one-way valve.

[0115] In another embodiment, the bioreactor can include a feed line positioned on top of the bioprocess container. The feed line can include a super-surface fluid discharge disposed above a volume of culture medium residing in the bioprocess container. The super-surface fluid discharge can be positioned such that fluid flowing through the fluid discharge directly contacts the culture medium contained within the bioprocess container. In one embodiment, the agitator can form a circumference when rotated, and the super-surface fluid discharge of the feed line can be positioned above the circumference of the agitator such that fluid passing through the fluid discharge contacts the culture medium within the circumference.

[0116] The bioreactor can be placed in operative association with a load cell to indicate the mass of the culture medium contained within the hollow enclosure. The bottom of the bioprocess container can have a dome shape to facilitate drainage. For example, the bioprocess container can include a drain line located at the bottom of the bioprocess container. The fluid collection device can be positioned between the hollow enclosure of the bioprocess container and the drain line. The fluid collection device can have a shape configured to induce a vortex flow of fluid from the bioprocess container to the drain line. In one embodiment, the drain line has a cross-sectional area proportional to the volume of the hollow enclosure. For example, for illustrative purposes, the drain line has a cross-sectional area of ​​about 0.4 mm per liter of hollow enclosure volume. 2 ~about 0.6mm 2 etc., about 0.3 mm 2 ~about 0.7mm 2 The cross-sectional area of ​​the slit may be 0.05 mm or less.

[0117] In one embodiment, the bioprocess container can include multiple ports for connecting to multiple supply lines for supplying fluids to the bioprocess container. Each port and corresponding supply line can include a matching indicator to assist a user in connecting the supply line to the corresponding port. The matching indicator can include, for example, a color such that each port and corresponding supply line is color coded. Matching indicators can also be applied to the feed lines and any corresponding ports, as well as the sparger and any corresponding connectors.

[0118] In one embodiment, the bioprocess container can include a port that includes a universal connector. The port can have a first end and a second end. The first end can be for forming a reconnectable attachment to a respective supply line. Each supply line can include a fluid filter disposed upstream from a corresponding port.

[0119] The present disclosure is also directed to a bioreactor system. The bioreactor system can include a bioprocess container made from a liquid impermeable and flexible form-fitting material. The bioprocess container can have a top, a bottom, and at least one sidewall therebetween. The bioprocess chamber can define a hollow enclosure for receiving a culture medium. The bioprocess container can also include a plurality of inlet ports for supplying materials to the hollow enclosure. A drain line can be positioned at the bottom of the bioprocess container for draining fluids. The mixing device can extend into the hollow enclosure of the bioprocess container and can include a rotatable shaft coupled to at least one agitator.

[0120] The bioreactor system may further include at least one sensor operatively associated with the bioprocess container for monitoring at least one parameter within the hollow enclosure. The at least one sensor may include a pH sensor, a dissolved carbon dioxide sensor, a dissolved oxygen sensor, a redox sensor, a load cell, a temperature sensor, or a tachometer. A controller may be disposed in communication with the at least one sensor. The controller may be configured to receive information from the at least one sensor and, based on the information, control a fluid supply to vary a flow rate of fluid from the fluid supply to the hollow enclosure of the bioprocess container to maintain at least one parameter of the culture medium contained within the hollow enclosure within preset limits.

[0121] For example, in one embodiment, the bioreactor system can include a carbon dioxide gas supply in fluid communication with the bioprocess container, and a liquid alkali supply also in fluid communication with the bioprocess container. The at least one sensor can include a pH sensor, and the controller can be configured to adjust the pH level of the culture medium within pre-set limits by adding an amount of carbon dioxide gas from the carbon dioxide gas supply to selectively lower the pH, or an amount of alkali from the liquid alkali supply to selectively increase the pH. In one embodiment, the system can include both a first pH sensor and a second pH sensor in communication with the controller.

[0122] In yet another embodiment, the bioreactor system can include an oxygen gas supply and the at least one sensor can include a dissolved oxygen sensor. The controller can regulate the dissolved oxygen level in the culture medium within predetermined limits by periodically adding an amount of oxygen gas from the oxygen gas supply to the culture medium based on information received from the dissolved oxygen sensor.

[0123] In yet another embodiment, the bioreactor system may include a carbon dioxide gas supply and the at least one sensor may include a dissolved carbon dioxide sensor. The controller may be configured to regulate the dissolved carbon dioxide level in the culture medium within preset limits by periodically adding an amount of carbon dioxide gas from the carbon dioxide gas supply to the culture medium based on information received from the dissolved carbon dioxide sensor.

[0124] In yet another embodiment, the bioreactor system can include a thermal jacket surrounding the bioprocess container. The thermal jacket can be in fluid communication with at least one of a heated fluid or a cooled fluid. The bioreactor system can further include a temperature sensor for sensing a temperature of a culture medium contained within the bioprocess container. The temperature sensor can be in communication with a controller. The controller can be configured to receive information from the temperature sensor and, based on the information, control a flow of fluid into the thermal jacket to increase or decrease a temperature of the culture medium contained within the bioprocess container to maintain the culture medium within preset temperature limits.

[0125] In another embodiment, the bioreactor system can further include a tachometer for monitoring a rotational speed of a rotating shaft coupled to the at least one agitator. The tachometer can be in communication with the controller. The controller can be in communication with a motor that rotates the shaft. The controller can be configured to control the motor in a manner that rotates the shaft at a predetermined speed based on information received from the tachometer.

[0126] The controller may include one or more microprocessors.

[0127] In one embodiment, the controller may be configured to receive information from multiple sensors to control multiple parameters within the bioreactor.

[0128] In one embodiment, one or more of the above-mentioned sensors may be incorporated into the bioprocess container and may be disposable along with the bioprocess container.

[0129] The present disclosure is also directed to a bioreactor including a bioprocess container made from a liquid impermeable and flexible conformable material. The bioprocess container can have a top, a bottom, and at least one sidewall therebetween. The bioprocess chamber can define a hollow enclosure for receiving a culture medium. At least one supply line can extend into the hollow enclosure for supplying fluid to the bioprocess container.

[0130] In one embodiment, the feed line includes a subsurface fluid outlet positioned adjacent to the agitator. The fluid outlet can be associated with a fluid control device that only allows fluid to flow out of the fluid outlet and prevents fluid from flowing in the reverse direction.

[0131] In an alternative embodiment, the feed line may include a super-surface fluid discharge disposed above the volume of culture medium present in the bioprocess container. The super-surface fluid discharge may be positioned such that fluid flowing through the fluid discharge comes into direct contact with the culture medium contained within the bioprocess container without contacting the sidewalls.

[0132] In one embodiment, the bioreactor can include a first feed line that includes a subsurface fluid outlet and a second feed line that includes a supersurface fluid discharge. In one embodiment, the bioreactor can contain about 1 to about 5 feed lines, such as about 2 to about 3 feed lines with supersurface fluid discharges.

[0133] In yet another embodiment, the disclosure is directed to a method of manufacturing a single-use bioreactor. The method includes constructing a bioprocess container from a liquid impermeable and flexible form-conforming material. The bioprocess container has a top, a bottom, and at least one sidewall therebetween. The bioprocess chamber defines a hollow enclosure for receiving a culture medium. The hollow enclosure can have a volume of about 1-250 milliliters, 250 milliliters-50 liters, 50-800 liters, or 800-200,000 liters. The bioprocess container includes a plurality of inlet ports for supplying materials to the hollow enclosure of the bioprocess container. Each inlet port has a diameter.

[0134] A mixing device is inserted into the hollow housing. The mixing device comprises a rotatable shaft coupled to at least one agitator. At least one sparger is also inserted into the hollow enclosure of the bioprocess container. The sparger comprises a gas tube having a longitudinal portion and a lateral portion. The longitudinal portion extends vertically into the hollow enclosure. The lateral portion is located at an end of the longitudinal portion below the agitator. The lateral portion defines a plurality of holes for releasing gas into a culture medium contained within the bioprocess container. The plurality of holes has a diameter.

[0135] The drain line is connected to the bottom of the bioprocess container. The drain line has a cross-sectional area.

[0136] According to the present disclosure, the diameter of the inlet port, the diameter of the holes on the sparger, and the cross-sectional area of ​​the drain line are proportional to the volume of the hollow enclosure. For example, the drain line may have a cross-sectional area of ​​approximately 0.3 mm per liter of hollow enclosure volume. 2 ~about 0.7mm 2 The cross-sectional area of ​​the slit may be 0.05 mm or less.

[0137] The present disclosure is also directed to a bioreactor including a bioprocess container made from a liquid impermeable and flexible conformable material. The bioprocess chamber can define a hollow enclosure for receiving a culture medium and can include at least one inlet port. A mixing device including a rotatable shaft coupled to a plurality of agitators can extend into the hollow housing of the bioprocess container.

[0138] According to the present disclosure, the bioreactor may further include a cell retention chamber in fluid communication with the hollow enclosure of the bioprocess container. A filtrate outlet may be disposed in fluid communication with the cell retention chamber. The filtrate outlet includes a biofilter that is permeable to liquids but impermeable to biological material contained in the culture medium. The filtrate outlet is for continuous or periodic removal of liquid from the cell retention chamber. The flow regulator is configured to alternate the flow of culture medium between the hollow enclosure of the bioprocess container and the cell retention chamber to perform a perfusion process.

[0139] The flow regulator can be in communication with, for example, a pressurized gas source and a vacuum source. The flow regulator can alternatively be configured to apply vacuum or gas pressure to the fluid contained in the cell retention chamber to recycle the fluid back and forth between the hollow enclosure of the bioprocess container and the cell retention chamber.

[0140] In one embodiment, the flow regulator can include a reciprocating diaphragm that alternates between applying pressure and suction to the fluid contained in the cell retention chamber.

[0141] The present disclosure is also directed to a bioreactor including a bioprocess container made from a liquid-impermeable and flexible form-fitting material. The bioprocess container defines a hollow housing for receiving a culture medium. A mixing device including a rotatable shaft coupled to at least one agitator can extend into the hollow enclosure of the bioprocess container. According to the present disclosure, the agitator is foldable onto the rotating shaft. For example, the agitator can include an impeller including at least one blade element. The blade element can be folded towards the rotatable shaft. In one embodiment, the rotatable shaft is coupled to a first impeller and a second impeller, both impellers can include at least one foldable blade element. A retaining ring can be positioned on the shaft. The retaining ring can include an agitator-engaged position and an agitator-disengaged position for holding the agitator in an upright position during mixing or in a folded and folded position, respectively.

[0142] In one embodiment, the rotatable shaft includes a metal reinforcing rod surrounded by a shaft sleeve. A stainless steel metal reinforcing rod can attach the multiple pieces together. The top of the reinforcing rod can include a magnetic member for magnetically engaging the motor. The shaft sleeve can be constructed from a polymeric material. The agitator on the shaft can also be made from a polymeric material, such as a hydrophilic polymer. For example, the shaft sleeve and agitator can include a polyethylene polymer that has been modified by irradiation, photo or plasma induction, or by being subjected to oxidation.

[0143] In one embodiment, a single-use bioreactor system according to the present disclosure includes a single-use cell culture bioprocess container ("SUB"), a reusable shell in which the SUB is held during operation, and a controller that controls the operation of the SUB and associated subsystems and processes. The associated subsystems include an agitation system, a baffle system, a sparger system, a feed system, a harvest system, a monitoring system, a control system(s), and a filling system.

[0144] In one embodiment, each of the cell culture contacting surfaces and the process fluid contacting surfaces are preferably free of animal-derived components.

[0145] According to one aspect of the present disclosure, a single-use bioreactor is provided. The single-use bioreactor may include a bioprocess vessel, a shell, at least one agitator, at least one sparger, at least one gas filter inlet port for the sparger(s) and headspace overlay, at least one fill port, at least one harvest port, at least one sample port, and at least one probe.

[0146] The single-use bioreactor of the present disclosure may also be used with a single-use bioreactor (SUB) system, which may include a single-use and disposable flexible bioreactor bioreprocessing container, a SUB shell configured to hold the flexible bioreactor bioreprocessing container, an agitator, a sparger, a number of ports, and at least one controller configured to control a number of parameters associated with the SUB system, such that the SUB system produces biomaterials corresponding to those that can be produced in a similarly sized stainless steel bioreactor.

[0147] According to the present disclosure, the rotatable shaft can be coupled to an upper impeller and a lower impeller. Both the upper impeller and the lower impeller can be made of a polymeric material. For example, in one embodiment, the impellers can be 3D printed. Both the upper impeller and the lower impeller can define a hydrophilic surface. For example, the polymeric material used to form the impeller can include a hydrophilic polymer or can include a polymer that has been surface-modified to render the surface hydrophilic.

[0148] In one embodiment, for example, the upper and lower impellers are made from a polyolefin polymer, such as polyethylene or polypropylene. In one embodiment, low density polyethylene can be used. The low density polyethylene can be modified by irradiation, light or plasma induction, or by oxidation to form a hydrophilic surface.

[0149] The top impeller may comprise a hydrofoil impeller, while the bottom impeller may comprise a four pitch-bladed high solids impeller. The impeller-to-tank diameter ratio may be from about 0.35 to about 0.55, such as from about 0.44 to about 0.46. The top and bottom impellers may have a power number (N) of from about 0.1 to about 0.9. p ) and a flow rate number (N q ).

[0150] In an embodiment, the bioreactor of the present disclosure is the bioreactor described in U.S. Patent No. 9,670,446, the entirety of which is incorporated herein by reference. In an embodiment, the bioreactor of the present disclosure includes portions or features of the bioreactor described in U.S. Patent No. 9,670,446.

[0151] In one embodiment, the bioreactor can be operably coupled to a harvest vessel, e.g., a collection vessel. The harvest vessel may include a means for mixing the culture with a gas (e.g., to aerate the culture), e.g., to ensure proper oxygenation of the culture. In one embodiment, the harvest vessel includes within the harvest vessel the supernatant, e.g., deposited from the bioreactor, and a head space containing a gas, e.g., air, oxygen, or a mixture of air and oxygen. In one embodiment, the harvest vessel uses surface aeration to oxygenate the culture supernatant with a head space gas, e.g., air or oxygen, or a mixture of air and oxygen gas. Surface aeration involves cascading or flowing the supernatant from the J-tube inlet port down the harvest vessel wall and from the surface of the supernatant liquid in contact with the head space. In certain embodiments, the movement or cascading results in an increase in the oxygenation level of the culture.

[0152] The collection vessel may include at least one mixer, at least one gas filter inlet port for head space overlay, at least one fill port with an internal J-tube directed toward the vessel wall, at least one collection port, at least one sample port, at least one temperature probe, at least one redox probe, at least one DOT probe, and at least one pH probe, at least one temperature control, at least one gas flow, e.g., at least one air flow control, and at least one O2 flow control.

[0153] In one embodiment, the collection vessel contains a head space gas mixture of air / O2 that maintains the DOT in the range of greater than 40% air saturation to less than or equal to 500% air saturation.

[0154] In one embodiment, the bioreactor or harvest vessel comprises a redox probe, for example, an in-line redox probe, for example, a Mettler Toledo in-line redox probe.

[0155] In certain embodiments, the methods include a bioreactor or harvest vessel in which components of the thioredoxin or glutathione / glutaredoxin systems can be provided, e.g., added or modulated, e.g., increased or decreased in activity / abundance to provide or maintain a redox potential in the cells of the culture or culture supernatant. The thioredoxin and glutathione / glutaredoxin systems and their components are known in the art. See, for example, Holmgren et al., Biochem Soc Trans. 2005 Dec;33(Pt 6):1375-7; Nordberg and Arner. Free Radic Biol Med. 2001 Dec 1;31(11):1287-312; Ghezzi P. Biochem Soc Trans. 2005 Dec;33(Pt 6):1378-81; Ivarsson et al., Diabetes. 2005 Jul;54(7):2132-42; Sen, CK. Biochem Pharmacol 55(11),1747-1758. 1998 Jun 01; and May et al., J Biol Chem. 1997 Sep 5, 272(36):22607-10, the contents of which are incorporated herein by reference in their entireties.

[0156] In one embodiment, the method includes, or the bioreactor or harvest vessel can provide, for example, adding or modulating, e.g., increasing or decreasing, the activity / abundance of GILT (gamma interferon-inducible lysosomal thiol reductase). See, e.g., Rausch and Hastings. Mol Immunol. 2015 Dec;68(2PtA):124-8. doi:10.1016 / j.molimm.2015.06.008. Epub 2015 Jun 23, and Hastings and Cresswell. Antioxid Redox Signal. 2011 Aug 1;15(3):657-668, the contents of which are incorporated herein by reference in their entireties. In one embodiment, the method includes, or the bioreactor or harvest vessel can provide, for example, by adding ascorbic acid, dehydroascorbic acid, or an ascorbic acid or dehydroascorbic acid modifying component to the growth culture. The redox potential modulating properties of ascorbic acid and dehydroascorbic acid are known in the art. See, for example, Winkler et al., Free Radic Biol Med. 1994 Oct;17(4):333-49, which is incorporated herein by reference in its entirety.

[0157] In one embodiment, the method includes a bioreactor that can provide an intracellular agent, for example, add a redox potential indicator label, for example, a redox sensitive dye or molecular probe, to the production culture. Such redox potential indicator labels can be useful for monitoring the redox potential of the culture or cells within the culture. Redox potential indicator labels include, but are not limited to: 2,2'-bipyridine (Ru complex), nitrophenanthroline (Fe complex), N-phenylanthranic acid, 1,10-phenanthroline iron(II) sulfate complex (ferroin), N-ethoxychrysodine, 2,2'-bipyridine (Fe complex), 5,6-dimethylphenanthroline (Fe complex), o-dianisidine, sodium diphenylamine sulfonate, diphenylbenzidine, diphenylamine, viologen, sodium 2,6-dibromophenol-indophenol, sodium 2,6-dichlorophenol-indophenol, sodium-cresol indophenol, thionine (Lauth's violet), methylene blue, indigo tetrasulfonic acid, indigo trisulfonic acid, indigo carmine (indigo sulfonic acid), indigo monosulfonic acid, phenosafranine, safranine, neutral, the labels disclosed in any of the documents incorporated herein, and Schwarzlander M et al., Antioxid Labels disclosed in Redox Signal. 2016 May 1;24(13):680-712, which is incorporated herein by reference in its entirety.

[0158] In another embodiment, the method includes providing an extracellular agent, e.g., a metabolite, transition state metal ion as described herein, to the production culture, or the bioreactor or harvest vessel can do so.

[0159] In certain embodiments, a bioreactor or bioreactor(s) for use in the methods of the present disclosure can be set up according to the following principles. · The functional setup of the bioreactor while the production culture is being harvested is critical in ensuring that the culture exiting the bioreactor is well oxygenated and carries dissolved oxygen to the next processing step. Once the cell culture reaches the target temperature and begins the harvest step, ensure that all process controls that are likely to antagonize oxygenation of the production culture are inhibited. These may include inhibiting sparge nitrogen gas flow if active, inhibiting on-demand CO2 gas flow control if active, inhibiting on-demand alkali control if active, and inhibiting feed application if active.

[0160] Nitrogen sparge gas flow is typically used as a ballast to control the dissolved oxygen tension (DOT) at a set value when the cellular demand for oxygen is low, but can continue to flow actively during the production phase. Nitrogen is also used in airlift bioreactors as a carrier ballast to maintain mixing in these vessels. However, when nitrogen sparge gas is used, it must be inhibited to prevent diluting the oxygen composition of the sparge gas used to aerate the production culture during the harvest step. This is to prevent the dissolved oxygen, DOT in the culture from reaching 100% air saturation (if an air-only sparge is used) or the maximum expected DOT (if an air-oxygen blend is used). Thus, sparge nitrogen limits the maximum dissolved oxygen concentration expected for a given air-alone or air-oxygen mixture sparge. CO2 gas flow is sparged into the production culture in response to the process pH rising above the control range. If the CO2 gas flow sparge is active, it also dilutes the oxygen composition of the sparge gas, which limits the maximum dissolved oxygen concentration expected for a given air-only or air-oxygen mixture sparge. Thus, its inactivation during production culture harvest prevents dilution of the breathable sparge gas.

[0161] · Tight pH control during production culture requires the addition of alkaline solution to the production culture in response to the process pH dropping below the control range. However, the continuous reduction in working volume and overdosing of alkaline solution can result in greater cell damage and cell death with the application of alkaline solution while the production culture is being harvested. Application of feed to the production culture is necessary while the culture is actively growing and metabolizing. However, during harvest, the continuously decreasing working volume affects the mixing behavior of the bioreactor, resulting in greater cell damage and cell death with the application of feed solution due to the non-physiological nature of the feed (high osmolality and high or low pH) as well as the microenvironment created in a poorly mixed vessel.

[0162] · Ensure that the production culture reaches the target temperature, initiates the harvest step, and that all process controls likely to promote oxygenation of the production culture are activated. These may include activation of sparge air and / or oxygen gas flows if not active, activation of headspace air and / or oxygen flows if not active, and finally activation of headspace pressure if not active. On-demand air and / or oxygen sparge flows may be very low or stopped after the production culture has stopped growing or even after it has cooled down, at the ready for harvest state. Continuous application of air and oxygen sparge at various continuous fixed flow rates is important to oxygenate the production culture and ensure that the production culture delivers dissolved oxygen into the cells, clarifying the centrifuge and flow paths between the bioreactor and the filter housing or centrifuge, and between the filter housing or centrifuge and the supernatant collection vessel (e.g., harvest vessel). Headspace or overlay aeration is typically active during the cultivation of the production culture to ensure that the bioreactor headspace is continuously purged of metabolic CO2 gas. Continuous overlay aeration of the production culture during harvest promotes surface oxygenation of the culture, albeit slower than that achieved with sparge gas, but avoids foam generation while the production culture is being discharged from the bioreactor.

[0163] For bioreactors that can operate with headspace pressure and use pressure during production culture to improve solubility of gases into the liquid phase (culture) or to maintain a positive pressure within the bioreactor to prevent ingress of environmental contaminants beyond the sterile boundary of the vessel, it is recommended to maintain it during harvest. In practice, when the harvest is driven by pressure, culture oxygenation is assisted when the gas used to pressurize the bioreactor is air or a mixed blend of air and oxygen. However, when the harvest is driven by a pump, headspace pressure is typically not used. In such situations, the use of headspace pressure with air or an air / oxygen gas mixture is beneficial to assist in oxygenating the culture and to keep the harvest tubing from collapsing under the suction head upstream of the pump head when the culture is flowing at the fast rates required for the scale of operation required during the harvest operation.

[0164] In single-use bioreactors, the design of the harvest line in terms of internal bore size and wall strength to withstand collapse at high flow rates under the suction produced upstream of the pump head is critical to ensure that the harvest flow rate is not impeded by tubing blockage. The effects of tubing blockage may not only limit the harvest flow rate, but also promote greater cell death and cell lysis as well as degassing of dissolved oxygen from the culture. The effects of tubing blockage may expose the cells and product along with the filter housing to a hypoxic / anoxic environment by increasing residence time in the housing at slower flow rates, promoting release of intracellular factors through greater cell death and cell lysis through the constriction opening, and removing dissolved oxygen from the culture by degassing in the intake zone, thus reducing the amount of dissolved oxygen carried by the culture into the filter housing. In one embodiment, the method disclosed herein avoids these negative effects on product stability.

[0165] The choice of inner diameter of the collection tube and the pump used determines the process volumetric throughput (liters of process supernatant per filter area, L / m) of the cell clarification step by the depth filter or a centrifuge coupled to a depth filter. 2 ) is selected to achieve the flow rate required to achieve the required flow rate. The construction material of the collection line must be rigid enough to withstand the collapse of the suction head occurring upstream of the pump head. It has been suggested that materials other than the commonly used platinum-cured silicone or C-flex be used in the construction of the collection tube. The use of braided tubing could be considered as an alternative to the commonly used materials.

[0166] In certain embodiments, the method includes, or the bioreactor can enable, optimizing the depth filter area to avoid filter fouling and clogging during the filter clarification step, whereby minimizing residence time of the cell culture in the filter housing is an essential step to ensure that dissolved oxygen carried out from the production culture does not exit the bioreactor while the culture flows into and resides in the filter housing before passing through as supernatant. Additionally, the flow rate must be sufficient to minimize residence time of the supernatant between the clarification step (filter housing) and the supernatant collection vessel (e.g., harvest vessel).

[0167] The cell clarification filter (primary, secondary, tertiary) area is determined by the flux (L / m2) across the filter to the extent that the required process volumetric throughput impacts the performance of the secondary or stage 2 and tertiary or stage 3 filters downstream of the primary or stage 1 filter. 2 / h) or is optimized to be filled without compromising filtrate quality (due to particle breakthrough). Furthermore, the filter area and filter type selected for optimal cell clarification must avoid higher pressure differences between the different filter stages, which would mean filter fouling and immediate filter clogging. Thus, a reduction in flux across different serially coupled filters is expected to result in an increased residence time in the filter housing, leading to an increased consumption / depletion of dissolved oxygen in the supernatant in the filter housing, resulting in hypoxia in the supernatant. The accumulation of higher pressure differences between the primary and secondary stage filters is also problematic, as it promotes higher cell lysis and release of cellular factors that, when activated, destabilize the product.

[0168] In certain embodiments, the method includes, or the bioreactor can ensure, that the cell-free supernatant is collected in a well-aerated and mixed collection vessel (steel or single-use). The collection vessel is designed to promote good surface oxygenation by impinging the collected filtrate on the vessel wall surface by designing an internal nozzle directed at the vessel wall, and / or by filling the collection vessel with a gaseous environment composed of air or any given air and oxygen blend prior to filtrate collection to promote oxygenation of the collected filtrate to >40% air saturation and below 500% air saturation.

[0169] In one embodiment, the collection vessel is a stainless steel collection vessel. The method of supernatant collection and the design of the collection vessel are the final elements of the approach to protect the product during the collection process. Currently, the collected supernatant is collected in a jacketed stainless steel vessel using a mixer to continuously mix the collected supernatant. The collected supernatant is discharged through a head space port into the collection vessel using an internal "J" tube that directs the supernatant flow onto the vessel wall, from where it cascades down the wall to be collected at the bottom of the tank. Additionally, these stainless steel vessels are filled with sterile air to keep the vessel pressurized above atmospheric pressure after being steam sterilized to prevent the ingress of environmental contaminants beyond the sterile vessel boundary. It is hypothesized that the collected supernatant in these vessels is oxygenated as it cascades down the vessel wall under the atmosphere of pressurized air. Further oxygenation of the supernatant occurs through surface contact with the head space above the collected supernatant.

[0170] In another embodiment, the collection vessel is a single-use collection vessel. The single-use supernatant collection vessel is a gamma irradiation and drainage bag. During supernatant collection, the bag fills and displaces a vacuum without the formation of a gaseous head space above the collected supernatant. These bags do not have an agitator, so the collected supernatant cannot be mixed, and the bags are placed in an unjacketed plastic or stainless steel shell that does not allow the collected supernatant to be heated or cooled. Once the bags are filled with the supernatant, they are transferred to storage at +5°C for up to 14 days. The purification process can begin with the primary capture step immediately after collection or within the 14-day holding period.

[0171] The approach to ensure oxygenation of the production culture is maintained at a DOT ranging from greater than 40% air saturation to less than 500% during the harvest step, intended to "load" the production culture with dissolved oxygen that is expected to be carried into and through the clarification step, such that once the supernatant is collected, it has enough dissolved oxygen to prevent activation of cellular factors that may promote product dissociation. The harvest vessel is designed to continue to maintain a well-oxygenated state while the harvested supernatant is stored at +5°C for up to 14 days. This is accomplished by a vessel design that ensures that the supernatant remains oxygenated while collected and held under +5°C storage, for example, by surface aeration. In one embodiment, the harvest vessel design includes the following features: The vessel or single-use bag has an agitator / mixer that provides sufficient axial bulk mixing to oxygenate the collected supernatant through surface aeration. The container or single-use bag shell is jacketed with a suitably sized thermocirculator to enable the temperature of the container contents to reach, for example, +5°C from room temperature within 4 hours and to heat from +5°C to room temperature within a similar period. The container or single-use bag shell is fitted with appropriately sized air and oxygen gas mass flow controllers to allow for head venting with air, oxygen, or oxygen-enriched gas. · The vessel or single-use bag and shell is equipped with an overlay gas filter (suitable for air and oxygen gas at flow rates appropriate for the scale of operation) and an outlet gas vent filter suitable for air and oxygen gas at flow rates appropriate for the scale of operation to fill the collection vessel with air or any given blend of air and oxygen prior to supernatant filtrate collection, to promote oxygenation of the supernatant filtrate to >40%, and air saturation to 500% or less during and once collection is completed. · The container or single-use bags and shells are equipped with pressure sensors and safety interlocks that will shut off the headspace gas if pressure exceeds the safety limits of the scale of operation and container design. · Vessels or single-use bags and shells are fitted with process sensor ports for pH, DOT, redox and temperature. Probe locations within the vessel or bag allow monitoring at the smallest operating volume appropriate for the scale of operation. The container or single-use bag is fitted with an additional port at the top of the container that includes a port fitted with an internal nozzle that directs the flow of liquid to the container wall and encourages the liquid to cascade down the container wall.

[0172] Cells and cell culture In one aspect, the disclosure relates to methods and compositions for engineering or creating cells or cell lines that produce the products, e.g., recombinant products, described herein. In another aspect, the disclosure relates to methods and compositions for engineering or creating cells or cell lines that have improved, e.g., reduced dissociation, increased productivity, and / or product quality.

[0173] In an embodiment, the cell is a mammalian cell or a non-mammalian cell, such as an insect cell, a yeast cell, a fungal cell, a plant cell, an archaeal cell, such as a cell from an archaeal species, or a bacterial cell. In an embodiment, the cell is from a human, a mouse, a rat, a Chinese hamster, a Syrian hamster, a monkey, an ape, a dog, a duck, a horse, a parrot, a ferret, a fish, or a cat. In an embodiment, the cell is an animal cell. In an embodiment, the cell is a mammalian cell, such as a human cell or a rodent cell, such as a hamster cell, a mouse cell, or a rat cell. In an embodiment, the cell is a prokaryotic cell, such as a bacterial cell. In an embodiment, the cell is a species of Actinobacterium, such as Mycobacterium tuberculosis.

[0174] In one embodiment, the cell is a Chinese Hamster Ovary (CHO) cell. In one embodiment, the cell is a CHO-K1 cell, a CHO-K1SV cell, a DG44 CHO cell, a DUXB11 CHO cell, a CHOS, a CHO GS knockout cell, a CHO FUT8 GS knockout cell, a CHOZN, or a CHO-derived cell. The CHO GS knockout cell (e.g., a GSKO cell) is, for example, a CHO-K1SV GS knockout cell. The CHO FUT8 knockout cell is, for example, Potelligent® CHOK1 SV (Lonza Biologics, Inc.).

[0175] In another embodiment, the cell is HeLa, HEK293, HT1080, H9, HepG2, MCF7, Jurkat, NIH3T3, PC12, PER.C6, BHK (baby hamster kidney cells), VERO, SP2 / 0, NS0, YB2 / 0, Y0, EB66, C127, L cells, COS, e.g., COS1 and COS7, QC1-3, CHO-K1, CHOK1SV, Potelligent CHOK1SV, CHOGS knockout, CHOK1SV GS-KO, CHOS, CHO DG44, CHODUXB11, and CHOZN, or any cell derived therefrom. In one embodiment, the cell is a stem cell. In one embodiment, the cell is a differentiated form of any of the cells described herein. In one embodiment, the cell is a cell derived from any primary cell in culture.

[0176] In one embodiment, the cell is any one of the cells described herein that produces a product, e.g., a product described herein. In one embodiment, the cell is any one of the cells described herein that contains an exogenous nucleic acid encoding a recombinant polypeptide, e.g., expresses a recombinant polypeptide, e.g., a recombinant polypeptide selected from Tables 2 or 3.

[0177] In one embodiment, the cell culture (e.g., production culture) is performed as a batch culture, a fed-batch culture, an extract and feed culture, or a continuous culture. In one embodiment, the cell culture is an adherent culture. In one embodiment, the cell culture is a suspension culture. In one embodiment, the cell or cell culture is placed in vivo, e.g., in a model organism or a human subject, for expression of the recombinant polypeptide.

[0178] For example, the method is carried out in a large-scale bioreactor, such as a bioreactor having at least two impellers, a large-scale bioreactor system, and a method for the large-scale culture and growth of mammalian cells. In one embodiment, the bioreactor is a bioreactor as described in 2011 / 0312087.

[0179] In one embodiment, cells are cultured in a bioreactor as disclosed in U.S. Patent Application No. 62 / 242,758, the contents of which are incorporated herein in their entirety. Disclosed herein are systems and methods for control of a system containing at least one bioreactor, other cell culture related equipment, and any combination thereof. For example, systems and methods for bioreactor control may include controlling multiple bioreactors and other types of cultivation related equipment, such as equipment for fermentation, harvesting, microfiltration and purification (e.g., liquid chromatography skid systems), buffer preparation, media preparation, etc. Multiple bioreactors and other types of cultivation related equipment may be located within a plant, and the control of such equipment may be known as a plant-wide control system ("PWCS").

[0180] In one embodiment, the method is carried out in a manufacturing facility that provides both batch and continuous manufacturing, for example, using at least one disposable technology described in U.S. Patent Application No. 62 / 246,478, the contents of which are incorporated herein in their entirety. In one embodiment, the manufacturing facility is for the manufacture of active pharmaceutical ingredients ("APIs").

[0181] Cooling can be accomplished using methods known in the art. For example, larger reactors will typically have a water jacket through which thermostatically or temperature-controlled water is passed to control the culture temperature. In embodiments, a process cooling water supply is delivered into the jacket to obtain substantial and rapid cooling. In embodiments, a refrigeration unit is used to remove heat.

[0182] Cooling can be performed at one or more desired times, when culturing (i.e., increasing cell number or inducing production of a desired product from the cell culture), or when cooling the production culture at the end of the production phase, or when harvesting the cells. Since organisms differ in the optimal temperature at which they grow, the cooling temperature is selected based on the relatively high temperature of one or more steps prior to the cooling step. In an embodiment, cooling of cultured cells is performed to reduce the cellular rate of oxygen consumption so that the harvest stream remains oxygenated throughout the harvest process.

[0183] For mammalian cell lines, the temperature shift of the culture process is typically 27-35°C (e.g., 27, 28, 29, 30, 31, or 32, 33, 34, or 35°C). In certain embodiments, the temperature is reduced to 30-33°C after the exponential growth phase. Without wishing to be bound by theory, it is believed that reducing the temperature to 12-18°C, e.g., 15°C, after the production phase reduces the rate of oxygen consumption by 10-fold.

[0184] In one embodiment, the culture medium is serum-free.

[0185] Other suitable media and culture methods for mammalian cell lines are well known in the art, for example as described in US Pat. No. 5,633,162. Examples of standard cell culture media for laboratory flasks or low density cell culture, adapted to the needs of a particular cell type, are for example Roswell Park Memorial Institute (RPMI) 1640 medium (Morre, G., The Journal of the American Medical Association, 199, p. 519 f. 1967), L-15 medium (Leibovitz, A. et al., Amer. J. of Hygiene, 78, 1 p. 173 ff, 1963), Dulbecco's Modified Eagle's Medium (DMEM), Eagle's Minimum Essential Medium (MEM), Ham's F-12 medium (Ham, R. et al., Proc. Natl. Acad. Sc. 53, p288 ff. 1965), or Iscoves' Modified DMEM lacking albumin, transferrin and lecithin (Iscoves et al., J. Exp. med. 1, p. 923 ff., 1978). For example, Ham's F10 or F12 medium was specially designed for CHO cell culture. Other media specifically adapted for CHO cell culture are described in EP-481 791. Other suitable culture methods are known to those skilled in the art and may depend on the recombinant polypeptide product and the host cell used. It is within the skill of the art to determine or optimize suitable conditions for the expression and production of a product expressed by a cell, e.g., a recombinant polypeptide.

[0186] Assays for quantifying the amount, level, or quantity of a product produced or secreted, for example, secreted into culture medium, include protein quantification assays, for example, Bradford protein assay, SDS-PAGE analysis, immunoblots, for example, Western blots, and automated means, for example, using a Nanodrop device. Other methods for measuring increased protein production are well known to those skilled in the art. For example, increased recombinant protein production can be determined on a small scale by measuring the concentration in tissue culture medium by ELISA (Smales et al. 2004 Biotechnology Bioengineering 88:474-488). It can also be quantitatively determined by ForteBio Octet, for example, for high-throughput determination of recombinant monoclonal antibody (mAb) concentration in medium (Mason et al. 2012 Biotechnology Progress 28:846-855), or on a larger scale by Protein A HPLC (Stansfield et al. 2007 Bioengineering 97:410-424). Other methods for determining the production of a product, for example, a recombinant polypeptide as described herein, can refer to the specific production rate (qP) of the product, particularly the recombinant polypeptide in the cell, and / or the time integral of the viable cell concentration (IVC). In one embodiment, the method for determining production includes a combination of determining qP and IVC. Recombinant polypeptide production or productivity is defined as the concentration of the polypeptide in the culture medium, which is a function of these two parameters (qP and IVC), and is described in Porter et al. (Porter et al. 2010 Biotechnology Progress 26:1446-1455). Methods for measuring protein production are also described in more detail in the examples provided herein.

[0187] In one embodiment, the methods described herein produce cells with improved product quality. In one embodiment, the improved product quality results in an increase in product quality, for example, an increase of 1%, 2%, 3%, 4%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% or more, or an increase of 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 20-fold, 50-fold, or 100-fold or more, for example, compared to the amount, level, or quantity of product produced by cells that are not subjected to lower temperatures. Such an increase in product quality may be exemplified, for example, by one or more of the following: i) increasing or decreasing disulfide bond scrambling (e.g., increasing or decreasing a desired isoform or structure as a result of, for example, increasing or decreasing disulfide bond scrambling on an antibody molecule product); ii) an increase in the amount or quantity of non-aggregated products (or a decrease in the amount or quantity of aggregated products); iii) an increase in the amount or quantity of properly folded or assembled products (or a decrease in the amount or quantity of unfolded, unfolded, partially assembled, or unassembled products), or an increase in the ratio of properly folded or assembled products to unfolded, unfolded, partially assembled, or unassembled products; iv) an increase in the amount or quantity of full-length product (or a decrease in fragmentation of the product); v) an increase in desired post-translational modifications (or a decrease in unmodified or mismodified products); vi) increasing or decreasing glycan heterogeneity (e.g., for glycosylation products); vii) An increase in the amount or quantity of functional product (or a decrease in the amount or quantity of non-functional or dysfunctional product), or an increase in the ratio to functional or dysfunctional product.

[0188] Methods for measuring the quality of the product of a cell or cell line produced as described herein, e.g., improved product quality, are known in the art. In one embodiment, methods for determining the fidelity of the primary sequence of an expressed recombinant polypeptide product, e.g., mass spectrometry, are known in the art. The increase in the amount or concentration of a properly folded product, e.g., an expressed recombinant polypeptide, can be determined by evaluating circular dichroism or the intrinsic fluorescence of the expressed recombinant polypeptide. The increase in the amount or concentration of a functional product can be tested using various functional assays, depending on the identity of the recombinant product, e.g., the recombinant polypeptide. For example, antibodies can be tested by ELISA or other immunoaffinity assays. Other methods for determining the increase in product quality, e.g., determining aggregation, post-translational modifications, disulfide bond scrambling, can be evaluated by size exclusion chromatography, high performance liquid chromatography, dynamic light scattering (DLS) approaches, and protein electrophoresis (PAGE) methods.

[0189] In certain embodiments, additional steps may be performed to improve product expression, e.g., transcription, translation, and / or secretion of the product, or product quality, e.g., proper folding and / or fidelity of the primary sequence. Such additional steps include introducing an agent that improves product expression or product quality. In one embodiment, an agent that improves product expression or product quality may be a polypeptide that improves protein folding, e.g., a small molecule, polypeptide, or nucleic acid that encodes a chaperone protein. In one embodiment, an agent that assists in protein folding includes a nucleic acid that encodes a chaperone protein, e.g., BiP, PD1, or ERO1 (Chakravarthi &Bulleid 2004; Borth et al. 2005; Davis et al. 2000). Other additional steps to improve product yield and quality include overexpression of transcription factors such as XBP1 and ATF6 (Tigges & Fussenegger 2006; Cain et al. 2013; Ku et al. 2008), and lectin-binding chaperone proteins such as calnexin and caleticulin (Chung et al. 2004). Overexpression of agents that aid or improve protein folding, product quality, and product yield as described herein can be achieved by introduction of exogenous nucleic acids encoding the agents. In another embodiment, an agent that improves product expression or product quality is a small molecule that can be added to the cell culture to increase expression of the product or product quality, e.g., DMSO. In one embodiment, maintaining cells at a lower temperature than they normally grow, e.g., 1°C, 2°C, 3°C, 4°C, 5°C, 6°C, 7°C, 8°C, 9°C, or 10°C lower, can improve product quality by reducing or eliminating product dissociation.

[0190] Any of the methods described herein can further include an additional selection step to identify cells that have high productivity or produce high quality products. For example, FAC selection can be used to select specific cells that have a desired characteristic, such as higher expression of a protein folding protein, such as a chaperone.

[0191] In one aspect, the disclosure provides a method comprising a step for recovering or harvesting the recombinant polypeptide product. In embodiments in which the recombinant polypeptide is secreted from the cell, the method can comprise recovering, collecting, or isolating the recombinant polypeptide from the cell, a cell population, or a culture medium in which the cell is cultured. In embodiments in which the recombinant polypeptide is intracellular, purification of the recombinant polypeptide product comprises separating the recombinant polypeptide produced by the cell from one or more of host cell proteins, host cell nucleic acids, host cell lipids, and / or other debris from the host cell.

[0192] In embodiments, the process described herein provides a substantially pure protein product. As used herein, "substantially pure" means substantially free of pyrogens, substantially free of nucleic acids, and / or substantially free of endogenous cellular proteins from host cells, such as polymerases, ribosomal proteins, and chaperone proteins. A substantially pure protein product contains, for example, less than 25%, 20%, 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, or 1% of contaminating endogenous proteins, nucleic acids, or other macromolecules from host cells.

[0193] The method for recovering and purifying a product, for example, a recombinant polypeptide, is well established in the art. A physical or chemical or physicochemical method is used to recover a recombinant polypeptide product. The physical or chemical or physicochemical method can be a filtration method, a centrifugation method, an ultracentrifugation method, an extraction method, a lyophilization method, a precipitation method, a chromatography method, or a combination of two or more of these methods. In one embodiment, the chromatography method comprises one or more of size exclusion chromatography (or gel filtration), ion exchange chromatography, for example, anion or cation exchange chromatography, affinity chromatography, hydrophobic interaction chromatography, and / or multimodal chromatography.

[0194] In an embodiment, the reduction in temperature is combined with a reduction in temperature and a reduction in pH, a thioredoxin inhibitor, e.g., a metal ion. In an embodiment, this combined process is carried out in a bioreactor as described above. EXAMPLES

[0195] The present invention will be described in more detail by reference to the following examples. These examples are provided for illustrative purposes only and are not intended to be limiting unless otherwise specified. Therefore, the present invention should not be construed as being limited to the following examples in any way, but rather as embracing any and all variations that become evident as a result of the teachings provided herein.

[0196] Without further description, it is believed that one of ordinary skill in the art can, using the preceding description and the following illustrative examples, make and utilize the compounds of the present invention and practice the claimed methods. The following examples specifically point out various aspects of the present invention, and are not to be construed as limiting in any way the remainder of the disclosure.

[0197] Example 1. Background and Identification of Non-essential, Redundant, and / or Secreted Endogenous Proteins for Analysis Chinese Hamster Ovary (CHO) cells are the world's first production chassis for the generation of biopharmaceuticals (Walsh, 2014). Although a great deal of time, effort and expense is spent developing these cells from adherent cell lines to quiescent cells and then engineering the cells utilizing overexpression and synthetic elements to increase titer, growth rate and cell-specific recombinant protein production rate (qP), the cell chassis and genome remain effectively the same as the precursor Chinese Hamster. Because of this, the cells often behave as if they were within a Chinese Hamster instead of a completely artificial environment. This is exemplified by several seemingly functionally redundant genes that are still encoded and subsequently expressed by the cell line. There are literature examples of genes that have been successfully knocked down or knocked out of the CHO genome, leading to improved cell or product properties. These include knockdown of Cers2 and Tbc1D20 for specific productivity improvements (Pieper et al., 2017), Fut8 (to remove fucosylation), Bak and Bax (for higher resistance to apoptosis) (Grav et al., 2015), and ablation of endogenous CHO glutamine synthetase (Bebbington et al., 1992; Cockett, Bebbington, & Yarranton, 1990). The recent genome sequence for CHO (Lewis et al., 2013; Xu et al., 2011), and the promise shown by knockdown or knockout of individual genes with rapid advances in genome editing technologies (Cong, Ran, Cox, Lin, & Barretto, 2013; Ran et al., 2013) present an opportunity for greater screening of redundant elements within the CHO genetic code.

[0198] Omics-level data was utilized in the form of quantitative transcriptomics and proteomics paired with a series of bioinformatics tools and literature analysis to rationally identify high abundance non-essential proteins predicted to compete with target mAbs for the endoplasmic reticulum (ER) space, as well as post-translational modifications (PTMs) and secretion machinery. The strategy is based on the analysis of Lonza RNA-seq data from bioreactor experiments primarily on CHO cell lines. Samples were harvested and extracted on days 4, 7, and 9, and RNA-seq analysis was performed on the CHOK1GS (Ensembl accession number: CHOK1GS_HDv1) genome sequence. A measure of the amount each gene was expressed as part of the total cellular transcript pool was obtained by using the transcripts per million (TPM) value of each gene. Automated gene ID assignment yielded identities of 77.5%, 77.7%, and 77.6% of the total transcript pool active genes on days 4, 7, and 9. Manual assignment contributed gene IDs to 18.4%, 17.8%, and 18.3% of the transcript pool. This resulted in a total of 13773, 14433, and 14660 gene IDs for days 4, 7, and 9, and these assignments represent 95.7%, 95.4%, and 95.8% of the IDs in the total transcript pool for days 4, 7, and 9. Defined thresholds were then introduced to help classify gene transcripts into different abundance levels (based on Ramskold et al (2009) PLoS Comput. Biol. 2009 Dec;5(12):e1000598.doi:10.1371 / journal.pcbi.1000598). Non-expressed genes (fragments per kilobase of exon model per million mapped reads (FPKM) < 0.3) (TPM < 0.4) Low expression genes (0.3≦FPKM<3) (0.4≦TPM<4) Moderately expressed genes (3≦FPKM<30) (4≦TPM<40) Highly expressed genes (30≦FPKM<100) (40≦TPM<133.33) Very highly expressed genes (FPKM ≥ 100) (TPM ≥ 133.33)

[0199] Only genes that consistently met the very high abundance gene criteria over three days (days 4, 7, and 9) were advanced (879 genes). These genes were then passed through the Panther classification system (http: / / www.pantherdb.org / ) with the Mus musculus database used as the organism on which the analysis was performed. Initially, only genes containing keywords that were deemed of interest due to functional redundancy were highlighted for further analysis (Table E1). A list of functionally important or highly necessary keywords was then generated (Table E2). Genes containing these keywords were then removed from further analysis and, in the case of genes containing keywords from both Tables E1 and E2, were analyzed in depth for consideration of evidence on how important the gene is to the function of CHO cells. After filtering the genes through the defined criteria, 76 targets (112 when considering all isoforms) were left.

[0200] We then performed bioinformatics analysis using four different tools to focus on genes that further met our criteria for secreted proteins. SignalP 4.1 - (default settings - eukaryotes) - http: / / www.cbs.dtu.dk / services / SignalP / · TargetP 1.1 - (default settings - non-plants) - http: / / www.cbs.dtu.dk / services / TargetP / ·SecretomeP 2.0 - (change the setting to Mammal) - http: / / www.cbs.dtu.dk / services / SecretomeP / TMHMM 2.0 - (default settings) - http: / / www.cbs.dtu.dk / services / TMHMM /

[0201] Further omics-level data was generated using quantitative subcellular proteomic analysis of exponential and stationary phase cells of a CHO cell line. Data detailing the total protein biomass (taking into account the average copy number of the protein and its molecular weight), if present, for the target protein, was noted.

[0202] Utilizing previously published data on quantitative proteomic analysis of extracellular proteins present within CHO cell culture medium (Kumar et al. 2015 J Proteome Res. 2015 Nov 6;14(11):4687-703. doi:10.1021 / acs.jproteome.5b00588; Park et al. 2017 Sci Rep. 2017 Mar 10;7:44246. doi:10.1038 / srep44246.), we tried and identified common redundant extracellular host cell (HC) proteins. Whether target proteins from a predefined list were present and, if so, details of whether they were present at high, medium or low levels (criteria defined in Table E3) (NSAF - normalized spectral abundance factor, NSC - normalized spectral count) were noted.

[0203] The summarized pipeline is shown below: 1. All transcripts were very high throughout the culture in the bioreactor 2. All contained at least one of the highlighted keywords (Table E1) 3. All essential keywords have been removed unless they conflict with point 2, for which an individual evaluation was performed (Table E2). 4. All are predicted to be secreted proteins by multiple bioinformatics tools 5. Matching Attempts for Lonza IC Proteomics 6. Attempt to match previously published CHO EC abundance data 7. Attempt to identify carbohydrates and carbohydrate / AA using Mus musculus Uniprot data 8. Ranked according to defined criteria (Table E4)

[0204] A further set of a priori targets (fibronectin - Fn1 and heparin sulfate proteoglycan - HSPG2) were selected due to their perceived redundancy, alongside two negative targets that match most of the criteria defined above but appear to be crucial for a functioning CHO cell expression system (clusterin - Clu and 14-3-3 protein epsilon - YWHAE). The final list of 20 targets tested is shown in Table E5.

[0205] Example 2: Knocking out an endogenous protein and increasing product yield Highly specific targeted knockdown of designated genes, e.g., genes encoding endogenous proteins, e.g., extracellular proteins, secreted proteins, and / or redundant proteins (e.g., genes determined in Example 1, e.g., Table E5), was performed through the use of Cas9 nuclease and the impact on recombinant protein production was evaluated. The use of enhanced specificity Cas9 fused to GFP (eCas9 1.1) (Slaymaker et al., 2016) 2A peptide allows high throughput isolation of cells with Cas9 nuclease activity, potentially enabling multiplex genome editing (Lonowski et al. 2017 Nat Protoc. 2017 Mar;12(3):581-603. doi:10.1038 / nprot.2016.165).

[0206] By successfully knocking out genes encoding endogenous proteins, e.g., extracellular, secreted, and / or redundant proteins, a minimal CHO genome can be created that lacks redundant and competing proteins (e.g., proteins that compete for translation (i.e., mRNAs that code for proteins), as well as ER / Golgi resources that compete with the product (i.e., mRNAs that code for products)). This helps generate a more streamlined genome and proteome, with improved growth and production characteristics that are better suited to the high titer and growth rate demands necessary for the generation of competitive biopharmaceuticals.

[0207] In one embodiment, knockout of functionally redundant secretion genes from the CHO genome generates enhanced cell lines capable of enhanced growth rates and expression capabilities.

[0208] To initially screen for gene knockout targets identified in Table E5, each gene target was individually knocked out from an IgG4 Mab-producing clonal GS-CHOK1SV cell line by transient transfection with a plasmid (pX458) encoding both the Cas9-GFP nuclease described above as well as gene target-specific guide RNA(s) expressed from a constitutive U6 promoter. Forty-eight hours after transfection, a heterogeneous pool of transfected cells was sorted by FACS for high GFP expression (a proxy for high Cas9 nuclease activity) and 0.5×10 6 The above surviving cells were selected and pooled for further culture and subsequent evaluation of growth, Mab productivity, and gene knockout success.

[0209] In detail, the GS-CHOK1V cell line, which produces IgG4 Mab, was transiently transfected with a plasmid (pX458) containing 1) a Cas9-GFP nuclease fusion protein expressed from a CMV promoter, and 2) guide RNA(s) specific for a target gene in its genome expressed from a constitutive U6 promoter. 48 hours after transfection, the transfectant pool was sorted by FACS for high GFP expression and ≥ 0.5 × 10 6 After 72 hours, the cell culture was centrifuged, the supernatant was removed, and the cell pellet was diluted to 0.2 × 10 cells in a new flask. 6 The cells were resuspended to a final concentration of 10 viable cells / mL and then grown for ≥5 days before Mab titers were determined by ValitaTITER (Valitacell, Dublin, Ireland) and cell numbers were determined by automated cell counting (ViCell-Beckman Coulter, High Wycombe, UK). Percent changes in qP were calculated for FACS-sorted pools of GS-CHOK1SV cells transfected with pX458 vectors containing gRNAs specific for the indicated target genes. All data points are expressed relative to control GS-CHOK1SV cells transfected with pX458 expressing a Cas9-GFP nuclease fusion protein but lacking gRNA.

[0210] Targeting Cas9-GFP nuclease to the genes Lamb1, Mfge8, Sbsn, C1S, C1R, Nid1, Dcn, B2M, and Clu with gRNAs increased the average qP of FACS-sorted pools of GS-CHOK1SV cells compared to control GS-CHOK1SV cells transfected with pX458 vector lacking gRNA ( Figure 1A ).

[0211] To determine the success of Cas9-GFP gene editing targeting the designated genes, genomic DNA was extracted from FACS-sorted cells and assessed by TIDE analysis (Brinkman et al. 2014, Nucleic Acids Res. 2014 Dec 16;42(22):e168. doi:10.1093 / nar / gku936). Results demonstrated a high rate of targeted gene indels achieved by this method, ranging from ≥60-90% (Figure 1B). This strongly suggests that the phenotypic readout (i.e., the observed increase in qP) is a function of gene editing in the pool.

[0212] Example 3: Multigene knockout of endogenous targets and increased product yield. The data presented in Example 2 partially suggests that several endogenous genes encoding non-essential, redundant, and / or secreted endogenous proteins in cells can be individually knocked out to increase the yield of Mabs from CHO cell lines. Because the number of endogenous proteins transiting the cellular secretion apparatus is so high, it is likely that multiple genes encoding essential, redundant, and / or secreted endogenous proteins will need to be removed to maximize the increase in qP obtained using this strategy. To test this, gene targets Lamb1, Mfge8, Sbsn, C1S, C1R, Nid1, Dcn, B2M, and Clu, which correlated with the highest increase in qP when knocked out individually, were knocked out in random triplet combinations in the GS-CHOK1SV cell line using the techniques of Examples 1 and 2 (Table E6), but combinations of targets located on the same CHO chromosome (C1S and C1R, Mfge8 and Nid1, and Dcn and Clu) were avoided to reduce the risk of large-scale genomic recombination. When combined in triplicates, several combinations of gene targets correlated with substantial increases in average titer and qP, e.g., C1S, Dcn, and Lamb1 showed an average increase in titer of 25% and qP of 28% when combined in triple knockout pools compared to control GS-CHOK1SV cells transfected with pX458 vector lacking gRNA (Table E7).

[0213] Example 4: Tables [Table 5]

[0214] [Table 6] TIFF2024161560000023.tif223149

[0215] [Table 7] TIFF2024161560000025.tif223149

[0216]

Table 8

[0217]

Table 9

[0218]

Table 10

[0219]

Table 11

[0220]

Table 12

[0221] Example 5: References Bebbington,RC,Renner,G.,Thomson,S.,King,D.,Abrams,D.,&Yarranton,GT(1992).High level expression of a recombinant antibody from myeloma cells using a glutamine synthetase gene as an amplifiable selectable marker.Nature Biotechnology,10,169-175. Brown,A.J.,Gibson,S.,Hatton,D.,&James,D.C.(2018).Transcriptome-Based Identification of the Optimal Reference CHO Genes for Normalisation of qPCR Data.Biotechnology Journal,13 (1),1-7.https: / / doi.org / 10.1002 / biot.201700259 Cockett,I.M.,Bebbington,R.C.,&Yarranton,T.G.(1990).High level expression of tissue inhibitor of met alloproteinases in chinese hamster ovary cells using glutamine synthetase gene amplification.Nature Biotechnology,8,662-667.https: / / doi.org / 10.1038 / nm0798-822 Cong,L.,Ran,F.,Cox,D.,Lin,S.,&Barretto,R.(2013).Multiplex genome engineering using CRISPR / Cas systems.Science,339 (6121),819-823.https: / / doi.org / 10.1126 / science.1231143.Multiplex Grav,L.M.,Lee,J.S.,Gerling,S.,Kallehauge,T.B.,Hansen,A.H.,Kol,S.,...Kildegaard,H.F.(2015).One-step generation of triple knockout CHO cell lines using CRISPR / Cas9 and fluorescent enrichment.Biotechnology Journal,10(9),1446-1456.https: / / doi.org / 10.1002 / biot.201500027 Kittler,R.,Surendranath,V.,Heninger,A.K.,Slabicki,M.,Theis,M.,Putz,G.,...Buchholz,F.(2007).Genome-wide resources of endoribonuclease-prepared short interfering RNAs for specific loss-of-function studies.Nature Methods,4 (4),337-344.https: / / doi.org / 10.1038 / nmeth1025 Kumar,A.,Baycin-Hizal,D.,Wolozny,D.,Pedersen,L.E.,Lewis,N.E.,Heffner,K.,...Betenbaugh,M.J.(2015).Elucidation of the CHO super-ome (CHO-SO) by proteoinformatics.Journal of Proteome Research,14 (11),4687-4703。https: / / doi.org / 10.1021 / acs.jproteome.5b00588 Lewis,N.E.,Liu,X.,Li,Y.,Nagarajan,H.,Yerganian,G.,O’Brien,E.,… Palsson,B.O.(2013).Genomic landscapes of Chinese hamster ovary cell lines as revealed by the Cricetulus griseus draft genome.Nature Biotechnology,31 (8),759-765.https: / / doi.org / 10.1038 / nbt.2624 Park,J.H.,Jin,J.H.,Lim,M.S.,An,H.J.,Kim,J.W.,&Lee,G.M.(2017).Proteomic analysis of host cell protein dynamics in the culture supernatants of antibody-producing CHO cells.Scientific Reports,7(November 2016),1-13.https: / / doi.org / 10.1038 / srep44246 Pieper,L.A.,Strotbek,M.,Wenger,T.,Gamer,M.,Olayioye,M .A.,&Hausser,A.(2017).Secretory pathway optimization of CHO producer cells by co-engineering of the mitosRNA-1978 target genes CerS2 and Tbc1D20.Metabolic Engineering,40(October 2016),69-79.https: / / doi.org / 10.1016 / j.ymben.2017.01.003 Ran,F.A.,Hsu,P.D.,Wright,J.,Agarwala,V.,Scott,D.A.,&Zhang,F.(2013).Genome engineering using the CRISPR-Cas9 system.Nature Protocols,8 (11),2281-2308.https: / / doi.org / 10.1038 / nprot.2013.143 Slaymaker,I.M.,Gao,L.,Zetsche,B.,Scott,D.A.,Yan,W.X.,&Zhang,F.(2016).Rationally engineered Cas9 nucleases with improved specificity.Science,351 (6268),84 -88.https: / / doi.org / 10.1126 / science.aad5227 Walsh, G. (2014).Biopharmaceutical benchmarks 2014.Nature Biotechnology ,32 (10),992-1000. Xu, X., Nagarajan, H., Lewis, NE, Pan, S., Cai, Z., Liu,

[0222] Equivalent Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein which equivalents are intended to be encompassed by the following claims.

[0223] The present invention includes all variations, combinations, and permutations in which one or more limitations, elements, clauses, and descriptive terms from one or more of the enumerated claims are introduced into another claim. When elements are presented as lists, for example, in Markush group format, or as alternatives, each subgroup of elements is also disclosed, and any element(s) can be deleted from the group.

[0224] In general, when the invention or aspects of the invention are referred to as comprising certain elements and / or features, it is to be understood that the particular embodiment of the invention or aspects of the invention consist of or consist essentially of such elements and / or features. It is also to be noted that the terms "comprising" and "containing" are intended to be open, allowing for the inclusion of additional elements or steps. When ranges are specified, the endpoints are included. Furthermore, unless otherwise indicated or clear from the context and understanding of one of ordinary skill in the art, values ​​expressed as ranges can assume in different embodiments of the invention any particular value or subrange within the stated range to the tenth of the unit of the lower limit of the range, unless the context clearly indicates otherwise.

Claims

1. 1. A method for producing a product, such as a recombinant polypeptide, in a cell, such as a production cell, comprising: Reducing the level of an endogenous protein in said cell, such as a production cell; thereby producing said product.

2. The method of claim 1 , wherein the cell is a production cell.

3. 3. The method of claim 1 or 2, further comprising culturing the cells under suitable conditions to produce the product, such as a recombinant polypeptide.

4. The method of any one of claims 1 to 3, further comprising providing a cell, such as a production cell.

5. 1. A method for producing a product, such as a recombinant polypeptide, in a cell, such as a production cell, comprising: Providing a cell, such as a production cell; reducing the level of an endogenous protein in said cell, such as a production cell; culturing said cells under conditions suitable for producing said product, such as a recombinant polypeptide; thereby producing said product.

6. 6. The method of any one of claims 1 to 5, further comprising harvesting the product, e.g., separating the product from a production mixture, and / or providing a purified preparation of the product, such as by a method described herein or known in the art.

7. 1. A method for producing a cell, such as a production cell, comprising: reducing the level of an endogenous protein in said cell, such as a producing cell; The method wherein said cell, such as a production cell, is capable of expressing a product, such as a recombinant polypeptide.

8. The method of claim 7, further comprising providing a cell, such as a production cell.

9. 9. The method of any one of claims 1 to 8, wherein the endogenous protein is a non-essential protein (e.g., reduced levels or complete loss of the protein does not significantly adversely affect cell viability or product production).

10. The method according to any one of claims 1 to 9, wherein the endogenous protein is an extracellular protein.

11. The method according to any one of claims 1 to 10, wherein the endogenous protein is a secreted protein.

12. The method of any one of claims 1 to 11, wherein the endogenous protein is localized in the Golgi apparatus.

13. The method of any one of claims 1 to 12, wherein the endogenous protein is localized in the endoplasmic reticulum (ER).

14. 14. The method of any one of claims 1 to 13, wherein the endogenous protein is a redundant protein (e.g., a functionality or activity of the protein significantly overlaps (e.g., partially or completely) with a functionality or activity of another endogenous protein present in the cell).

15. 15. The method of any one of claims 1 to 14, wherein the endogenous protein is identified and / or selected by the method of Example 1, e.g., by association with a keyword in Table E1, by non-association with a keyword in Table E2, and / or by being predicted to be a secreted protein.

16. 16. The method of any one of claims 1 to 15, wherein the endogenous protein is selected from Table E5.

17. 17. The method of any one of claims 1 to 16, wherein the levels of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more (e.g. 20 or more) endogenous proteins are reduced.

18. 18. The method of any one of claims 1 to 17, wherein the levels of endogenous proteins encoded by one, two or three genes of a gene combination listed in Table E6 are reduced.

19. 19. The method of any one of claims 1 to 18, wherein reducing the level of an endogenous protein in the cell comprises knocking out a copy of the gene encoding the endogenous protein from the genome of the cell, or knocking out or removing, such as knocking out, a regulatory nucleic acid sequence, such as a promoter or enhancer, operably linked to the gene encoding the endogenous protein.

20. 20. The method of any one of claims 1 to 19, wherein reducing the level of an endogenous protein in the cell comprises knocking out all (e.g. both) copies of the gene encoding the endogenous protein from the genome of the cell, or removing, such as knocking out, a regulatory nucleic acid sequence, such as a promoter or enhancer, operably linked to the gene encoding the endogenous protein.

21. 21. The method of claim 19 or 20, wherein removing, such as knocking out, comprises introducing a deletion, substitution, or insertion mutation into the gene encoding the endogenous protein or into the regulatory nucleic acid sequence, such as a promoter or enhancer, operably linked to the gene encoding the endogenous protein, e.g., the mutation reduces the expression level of the endogenous protein.

22. 22. The method of claim 21 , wherein removing, such as knocking out, comprises introducing a deletion or insertion of one, two, three, four, five, six, seven, eight, nine, ten or more base pairs into the gene encoding the endogenous protein or into the regulatory nucleic acid sequence, such as a promoter or enhancer, operably linked to the gene encoding the endogenous protein.

23. 22. The method of claim 21, wherein removing, such as knocking out, comprises substituting one, two, three, four, five, six, seven, eight, nine, ten, or more base pairs for a different base pair (e.g., a transition or transversion mutation) in the gene encoding the endogenous protein or in the regulatory nucleic acid sequence, such as a promoter or enhancer, operably linked to the gene encoding the endogenous protein.

24. 24. The method of any one of claims 19 to 23, wherein removing, such as knocking out, comprises using a CRISPR-Cas9 molecule, such as a Cas9 molecule, in combination with RNA (e.g., gRNA, sgRNA, and / or tracrRNA) specific for a gene encoding the endogenous protein or a regulatory nucleic acid sequence, such as a promoter or enhancer, operably linked to the gene encoding the endogenous protein.

25. Using the CRISPR-Cas9 molecule: providing within said cell a CRISPR-Cas9 molecule (e.g., a Cas9 molecule), e.g., and RNA (e.g., gRNA, sgRNA, and / or tracrRNA) specific to the gene encoding said endogenous protein or to said regulatory nucleic acid sequence, such as a promoter or enhancer, operably linked to said gene encoding said endogenous protein; or 25. The method of claim 24, comprising providing within the cell a nucleic acid encoding a CRISPR-Cas9 molecule (e.g., a Cas9 molecule), e.g., and an RNA (e.g., a gRNA, sgRNA, and / or tracrRNA) specific to a gene encoding the endogenous protein or to the regulatory nucleic acid sequence, such as a promoter or enhancer, operably linked to the gene encoding the endogenous protein.

26. 19. The method of any one of claims 1 to 18, wherein reducing the level of an endogenous protein in the cell comprises using an siRNA capable of binding to a nucleic acid, e.g. an mRNA, encoding the endogenous protein, or a regulatory nucleic acid sequence, e.g. a promoter or enhancer, operably linked thereto.

27. The use of siRNA may providing an siRNA in said cell; or 27. The method of claim 26, comprising providing a nucleic acid encoding the siRNA in the cell.

28. 28. The method of claim 26 or 27, wherein the siRNA is designed, selected, or produced by a method selected from the Dharmacon Horizon siDesign tool, InvivoGen siRNA Wizard, GenScript siRNA Construct Services, IDT Custom Dicer-Substrate siRNA, Sigma-Aldrich siRNA Design Service, or the method taught by www.rnaiweb.com / RNAi / siRNA_Design / , or an equivalent method thereof.

29. A cell, such as a production cell, capable of producing a product, such as a recombinant polypeptide, wherein the cell, such as a production cell, comprises a deletion, substitution, or insertion mutation in a copy of a gene encoding an endogenous protein, or in a regulatory nucleic acid sequence, such as a promoter or enhancer, operably linked to the gene encoding the endogenous protein, e.g., the mutation reduces the expression level of the endogenous protein.

30. The cell of claim 29, wherein the cell comprises a deletion, substitution, or insertion mutation in all (e.g., both) copies of the gene encoding an endogenous protein, or in the regulatory nucleic acid sequence, such as a promoter or enhancer, operably linked to the gene encoding the endogenous protein, e.g., the mutation reduces the expression level of the endogenous protein.

31. 31. The cell of claim 29 or 30, wherein the cell does not contain a functional copy of the gene encoding the endogenous protein, or a regulatory nucleic acid sequence, such as a promoter or enhancer, operably linked to the gene encoding the endogenous protein.

32. A cell, such as a production cell, capable of producing a product, such as a recombinant polypeptide, wherein the cell comprises, for example, a nucleic acid, such as an mRNA, encoding an endogenous protein, or a regulatory element, such as a promoter or enhancer, operably linked thereto, an siRNA capable of binding thereto.

33. 33. The cell of any one of claims 29 to 32, wherein the endogenous protein is a non-essential protein (e.g., reduced levels of the protein or complete loss of the protein does not significantly adversely affect cell viability or product production).

34. The cell of any one of claims 29 to 32, wherein the endogenous protein is an extracellular protein.

35. The cell according to any one of claims 29 to 32, wherein the endogenous protein is a secreted protein.

36. 33. The cell of any one of claims 29 to 32, wherein the endogenous protein is a redundant protein (e.g., a functionality or activity of the protein significantly overlaps (e.g., partially or completely) with a functionality or activity of another endogenous protein present in the cell).

37. 33. The cell of any one of claims 29 to 32, wherein the endogenous protein is selected from Table E5.

38. 38. The cell of any one of claims 29 to 37, wherein the cell further comprises a deletion, substitution, or insertion mutation in a copy of the gene encoding a second endogenous protein, or in a regulatory nucleic acid sequence, such as a promoter or enhancer, operably linked to the gene encoding the second endogenous protein, e.g., the mutation reduces the expression level of the second endogenous protein.

39. 39. The cell of claim 38, wherein the second endogenous protein is selected from Table E5.

40. 40. The cell of claim 38 or 39, wherein the cell further comprises a deletion, substitution, or insertion mutation in a copy of a gene encoding a third endogenous protein, or in a regulatory nucleic acid sequence, such as a promoter or enhancer, operably linked to the gene encoding the third endogenous protein, e.g., the mutation reduces the expression level of the third endogenous protein.

41. 41. The cell of claim 40, wherein the third endogenous protein is selected from Table E5.

42. 42. The cell of any one of claims 38-41, wherein the first and second, or first, second, and third endogenous proteins are encoded by two or three genes of a gene combination listed in Table E6.

43. The cell of any one of claims 29 to 42, wherein the endogenous protein is localized in the Golgi apparatus.

44. The cell of any one of claims 29 to 42, wherein the endogenous protein is localized in the endoplasmic reticulum (ER).

45. 45. The method or cell of any one of 1-44, wherein said cell, such as a production cell, is a CHO-K1 cell, a CHO-K1 SV cell, a DG44 CHO cell, a DUXB11 CHO cell, CHOS, a CHO GS knockout cell (e.g. a CHO-K1SV GS knockout cell), a CHO FUT8 GS knockout cell (e.g. Potelligent® CHOK1 SV), a CHOZN, or a CHO derived cell.

46. 45. The method or cell of any one of claims 1 to 44, wherein the cell, such as a production cell, is a CHO-GSKO cell, a CHO Xceed™ cell, a CHO GS knockout cell (e.g., a GS-CHO cell), a CHO-K1SV™ GS knockout cell, or a Potelligent® CHOK1 SV.

47. 45. The method or cell of any one of claims 1 to 44, wherein the cell, such as a production cell, is HeIa, HEK293, HT1080, H9, HepG2, MCF7, Jurkat, NIH3T3, PC12, PER.C6, BHK (baby hamster kidney cells), VERO, SP2 / 0, NS0, YB2 / 0, Y0, EB66, C127, L cells, COS, e.g., COS1 and COS7, QC1-3, CHOK1, CHOK1SV, Potelligent CHO K1SV, CHO GS knockout, CHOK1SV GS-KO, CHOS, CHO DG44, CHO DXB11, or CHOZN, or any cell derived therefrom.

48. 48. A product, such as a recombinant polypeptide, produced by the method or cell of any one of claims 1 to 47.

49. 49. A pharmaceutical composition comprising a product such as the recombinant polypeptide of claim 48.

50. 50. The pharmaceutical composition of claim 49, further comprising a pharma- ceutically acceptable carrier, diluent, or excipient.

51. 48. The method or cell of any one of claims 1 to 47, wherein said product, such as a recombinant polypeptide, comprises a bispecific antibody.

52. 48. The method or cell of any one of claims 1 to 47, wherein said product, such as a recombinant polypeptide, is a protein listed in Table 1, Table 2, Table 3, or Table 4.

53. 48. The method or cell of any one of claims 1 to 47, wherein the product is an antibody, for example a monoclonal antibody, such as an IgG1 antibody.

54. 48. The method or cell of any one of claims 1 to 47, wherein said cell, such as a production cell, is derived from a mammalian cell, such as a mouse, rat, Chinese hamster ovary cell (CHO) cell, Syrian hamster, monkey, ape, dog, horse, ferret, or cat cell.

55. 48. The method or cell of any one of claims 1 to 47, wherein said cell, such as a production cell, is derived from a non-mammalian cell, such as a cell from a duck, a parrot, a fish, an insect, a plant, a fungus, a yeast, a bacterium, such as E. coli, for example an Archaebacteria, or an Actinobacteria.

56. 48. The method or cell of any one of claims 1 to 47, wherein said cell, such as a production cell, is a stem cell.

57. 48. The method or cell of any one of claims 1 to 47, wherein the cell, such as a production cell, is a differentiated form of any of the cells described herein.

58. 48. The method or cell of any one of claims 1 to 47, wherein said cell, such as a production cell, is a cell derived from any primary cell in culture.

59. 48. The method or cell of any one of claims 1 to 47, wherein the cell, such as a production cell, is a CHOK1SV, GS-KO, or DUX-B11 cell.

60. 60. The method or cell of any one of claims 1 to 59, wherein the method is suitable for use in a bioreactor such as a bioreactor described herein or the cells are capable of being cultured / grown in a bioreactor such as a bioreactor described herein.

61. An siRNA capable of binding to a nucleic acid, such as an mRNA, that encodes an endogenous protein selected from Table E5.

62. 62. The siRNA of claim 61, wherein the siRNA is designed, selected, or produced by a method selected from the Dharmacon Horizon siDesign tool, InvivoGen siRNA Wizard, GenScript siRNA Construct Services, IDT Custom Dicer-Substrate siRNA, Sigma-Aldrich siRNA Design Service, or the method taught by www.rnaiweb.com / RNAi / siRNA_Design / , or an equivalent method thereof.

63. 63. The siRNA of claim 61 or 62 for use in a method or cell according to any one of claims 1 to 47 or 51 to 60.

Citation Information

Patent Citations

  • Engineered mammalian cells for production of recombinant proteins

    WO2017186671A1